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ABSTRACT 
It is well recognized that herbal supplements or herbal medicines are now commonly used. As 
many patients taking prescription medications are concomitantly using herbal supplements, 
there is considerable risk for adverse herbal drug interactions. Such interactions can enhance 
the risk for an individual patient, especially with regard to drugs with a narrow therapeutic 
index such as warfarin, cyclosporine A and digoxin. Herbal drug interactions can alter phar-
macokinetic or/and pharmacodynamic properties of administered drugs. The most common 
pharmacokinetic interactions usually involve either the inhibition or induction of the metabo-
lism of drugs catalyzed by the important enzymes, cytochrome P450 (CYP). The aim of the 
present article is to provide an updated review of clinically relevant metabolic CYP-mediated 
drug interactions between selected herbal supplements and prescription drugs. The commonly 
used herbal supplements selected include Echinacea, Ginkgo biloba, garlic, St. John's wort, 
goldenseal, and milk thistle. To date, several significant herbal drug interactions have their 
origins in the alteration of CYP enzyme activity by various phytochemicals. Numerous herbal 
drug interactions have been reported. Although the significance of many interactions is uncer-
tain but several interactions, especially those with St. John’s wort, may have critical clinical 
consequences. St. John’s wort is a source of hyperforin, an active ingredient that has a strong 
affinity for the pregnane xenobiotic receptor (PXR). As a PXR ligand, hyperforin promotes 
expression of CYP3A4 enzymes in the small intestine and liver. This in turn causes induction 
of CYP3A4 and can reduce the oral bioavailability of many drugs making them less effective. 
The available evidence indicates that, at commonly recommended doses, other selected herbs 
including Echinacea, Ginkgo biloba, garlic, goldenseal and milk thistle do not act as potent or 
moderate inhibitors or inducers of CYP enzymes. A good knowledge of the mechanisms of 
herbal drug interactions is necessary for assessing and minimizing clinical risks. These pro-
cesses help prediction of interactions between herbal supplements and prescription drugs. 
Healthcare professionals should remain vigilant for potential interactions between herbal sup-
plements/medicines and prescription drugs, especially for drugs with a narrow therapeutic in-
dex are used. 
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INTRODUCTION 
Products containing biologically active 
phytochemicals are often defined as “herb-
al” or “botanical” supplements. They are 
derived or extracted from a broad range of 
plant sources. Herbs and herbal supple-
ments are used by people for purpose of 
treating medical or psychiatric disorders. 
Herbal supplements are now commonly 
used in both Eastern and Western countries. 
Herbal medicines or traditional medicines 
have a long history of use in the Eastern 
countries, such as China and India, and con-
tinue to be used today (Philp, 2004). The 
use of herbal supplements in the United 
States has grown at a rapid rate with a 
380 % increase between 1990 and 1997 
(Brevoort, 1998; Eisenberg et al., 1998). 
The Dietary Supplement Health and Educa-
tion Act (DSHEA) of 1994 permits the di-
rect marketing of herbal products and sup-
plements without prior proof of safety or 
efficacy. Herbal supplements can be pur-
chased in several forms. The most common 
formulation of herbal supplements are en-
capsulated extracts. Herbal extracts, be-
cause they are crude products, usually con-
tain many natural phytochemicals. They are 
also accessible as tinctures and beverages 
(Markowitz et al., 2008). They can be in-
gredients in nutrition and sport drinks; 
powders, and “energy” bars. Patients may 
also consume food products containing cer-
tain phytochemical ingredients to treat 
common diseases. For instance, cranberry 
juice is widely used for urinary tract infec-
tions and garlic for hyperlipidemia (Mar-
kowitz et al., 2008).  
The perception that herbal supplements 
and medicines, legally categorized as over-
the-counter dietary supplements, may re-
duce or enhance the effects of prescription 
drugs has earned our attention slowly (Cott, 
2008). Herbal supplements usually have 
many active phytochemical constituents. 
Therefore, the possibility of interactions is 
increased when compared with the likeli-
hood of interactions between two prescrip-
tion drugs. Presently, most herbal drug in-
teractions are documented as case series or 
individual case reports (Sood et al., 2008). 
The common misconception is that herbal 
medicines or supplements are prepared 
from natural plants so therefore are safe to 
be taken concomitantly with prescription 
drugs. However, this does not guarantee 
that they are safe, free from adverse effects 
or toxicity, and devoid of any drug-drug 
interaction potential (Hermann and von 
Richter, 2012). The overwhelming majority 
of herbal use involves “self-medication” 
and these herbal products and supplements 
are commonly taken concomitantly with 
conventional medications with little or no 
information available on potential herbal 
drug interactions. Patients may feel embar-
rassed that they are self-medicating with 
complementary therapies and others may 
not consider that herbs are medicines in the 
conventional sense. A study in the United 
States revealed that only one-third of pa-
tients told their physician they were taking 
herbal remedies or supplements (Kennedy 
et al., 2008). In fact, there have been in-
creasing reports on herbal drug interactions. 
Drug interactions can be caused by some 
natural products which are not be consumed 
as medicines. Grapefruit and grapefruit 
juice is a common example. The first major 
concern of herbal drug interactions was 
recognised in 1989 when grapefruit juice 
was reported to increase the blood concen-
trations of felodipine, an anti-hypertensive 
calcium channel antagonist (Bailey et al., 
1998). Later in 1996, a similar grapefruit 
drug interaction was found with terfena-
dine, a non-sedative antihistamine (Bailey 
et al., 1998; Benton et al., 1996). Succes-
sive studies implied that these effects of 
grapefruit were caused by inhibition of in-
testinal CYP3A4 and a drug transporter 
protein, P-glycoprotein (P-gp) by furano-
coumarins (e.g. 6’, 7’-dihydroxybergamot-
tin, bergamottin and bergapten), naturally-
occurring ingredients in grapefruit (Bailey 
et al., 2000; Goosen et al., 2004; Ho et al., 
2001; Lin et al., 2012; Paine et al., 2005). 
Serious adverse drug reactions arising from 
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grapefruit and terfenadine interaction was 
one of the main reasons for withdrawal of 
terfenadine from the market in 1998. These 
adverse drug reactions were due to inhibi-
tion of CYP3A4 by grapefruit active ingre-
dients led to marked increase in blood ter-
fenadine concentrations. This subsequently 
caused prolonged QT intervals and follow-
ing cardiac arrhythmias. Grapefruits have 
also been shown to increase the plasma 
concentration and bioavailability of several 
drugs that are substrates for cytochrome 
P450 (CYP) 3A4 enzyme (Bailey et al., 
2007; Greenblatt et al., 2003). This means 
that grapefruit interacts with most clinically 
used drugs as more than 50 % of prescrip-
tion drugs are metabolized by CYP3A4 
(Guengerich, 1999; Nebert and Russell, 
2002). This made substantial concern re-
garding food or herbal drug interactions, 
and has also stimulated numerous research 
to fulfill the knowledge in this particular 
area. Cruciferous vegetables is an addition-
al example, it has been involved in the in-
teractions with a number of CYP1A2-
substrate drugs (Ioannides, 1999; Zhou et 
al., 2004). An understanding of these herbal 
drug interactions has great benefit for drug 
therapy as it helps us to predict herbal drug 
interactions. 
 
Herbal supplements and cancer  
chemoprevention 
For many years it has been recognized 
that the use of herbs as medicines plays an 
important role in nearly every culture, in-
cluding Asia, Africa, Europe and the Amer-
icas. Recent surveys suggest that one in 
three Americans use dietary supplements 
daily. It is interesting that the rate of herbal 
usage is much higher in cancer patients 
(Pierce et al., 2002; Richardson et al., 2000; 
Rock, 2003; Wargovich et al., 2001), in 
some cases, up to 50 % of patients treated 
in cancer centers. Many of these supple-
ments are herbal in nature (Wargovich et 
al., 2001). Herbal supplements are general-
ly taken for two main reasons. The first rea-
son is that they are used to alleviate symp-
toms of illness. For example, the wide-
spread use of St. John’s wort for relief of 
depression, the use of Echinacea for relief 
of cold symptoms, and use of Ginkgo bi-
loba for improvement in cognition (Wargo-
vich, 2001). The second reason is that herb-
al supplements are used specifically with 
the hopes of preventing disease or reducing 
the risk for certain diseases. Examples of 
this include green tea, grape seed extract 
and other flavonoid-rich botanicals which 
are taken because of their natural antioxi-
dants (Mandlekar et al., 2006). The use of 
garlic and its supplement preparation is an-
other example, which has been demonstrat-
ed in animals, to prevent cancer (Wargo-
vich, 1997; Wargovich et al., 2001). 
With respect to cancer chemopreven-
tion, herbal supplements can act through 
several mechanisms to provide a protective 
effect. Induction of phase I and phase II 
metabolic enzymes by herbal products is 
one of the common mechanisms (Wargo-
vich et al., 2001). Garlic as well as many 
organosulfur compounds derived from gar-
lic have been demonstrated to possess 
strong chemopreventive activity against ex-
perimentally induced cancers of the skin, 
esophagus, stomach, colon, liver, lung and 
mammary gland (Cerella et al., 2011; 
Chandra-Kuntal et al., 2013; Wargovich, 
1997; Wargovich et al., 2001). One of the 
active constituents in garlic, diallyl sulfide, 
is a potent inhibitor of the phase I enzyme 
CYP2E1 (Brady et al., 1988). CYP2E1 is 
involved in the metabolic activation of sev-
eral environmental and dietary carcinogens, 
e.g., nitrosamines (Yang et al., 2001; Zhou 
et al., 2003). In addition, diallyl sulfide sig-
nificantly increases a number of phase II 
enzymes, including glutathione S-trans-
ferase, UDP-glucuronosyltransferase, and 
quinone reductase. These phase II enzymes 
are responsible for the detoxification of 
many carcinogens (Wargovich, 1997; War-
govich et al., 2001). 
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Cytochrome P450 (CYP) 
CYP enzymes are responsible for detox-
ification of a wide range of xenobiotics in-
cluding drugs, environmental pollutants, 
and cancer-causing agents (i.e., carcino-
gens). They are also involved in the biosyn-
thesis of cholesterol and other important 
lipids such as prostacyclins and thrombox-
ane A2 which are implicated in the causa-
tion of many cardiovascular diseases 
(Guengerich, 1999; Nebert and Russell, 
2002). In fact, the role of CYP enzymes in 
protecting the body against foreign chemi-
cals is as crucial as that of antibodies in 
dealing with invading organisms. Most 
chemical carcinogens require metabolic ac-
tivation by CYP, to their genotoxic inter-
mediates (Guengerich and Shimada, 1991; 
Badal et al., 2012). In some instances, these 
activated metabolites are subjected to de-
toxification by conjugation reactions. Thus, 
activities or levels of CYP enzymes may be 
one of the important host factors which de-
termine whether exposure to the carcinogen 
results in cancer or not (Maliakal et al., 
2011; Nebert, 1991). The CYP1A subfami-
ly (CYP1A1 and CYP1A2) plays a vital 
role in the metabolism of two important 
classes of environmental carcinogens: poly-
cyclic aromatic hydrocarbons and aryla-
mines. Many clinically-important drugs are 
metabolized by this specific isoenzyme 
such as caffeine, theophylline, verapamil 
and clozapine. CYP2D6 is responsible for 
the metabolism of more than 30 clinically 
important drugs, such as metoprolol and 
several other β-blockers, antiarrhythmics, 
antidepressants, neuroleptics and morphine-
related drugs (Gonzalez, 1992). More than 
50 % of all prescription drugs are metabo-
lized by CYP3A4 (Guengerich, 1999; Ne-
bert and Russell, 2002). The activity of 
CYP can be influenced by many factors; 
including genetic composition of the host, 
certain medications, and exposure to certain 
dietary and environmental chemicals 
(Weisburger and Chung, 2002). It has been 
demonstrated that vegetables, particularly 
cruciferous ones (e.g., cabbage, brussel 
sprouts and cauliflower), induce CYP en-
zymes; namely CYP1A1 and CYP1A2 
(Murray, 2006; Yoshida et al., 2004; Zhou 
et al., 2004). Cigarette smoking is known to 
induce CYP1A1 and CYP1A2; the high 
levels of these CYP enzymes have been 
linked to an increased risk of lung and co-
lon cancer (Guengerich and Shimada, 1991; 
Smith et al., 2001; Zhou et al., 2010). 
CYP3A4 is the most important human 
CYP isozyme as it is involved in the me-
tabolism of most clinically used drugs 
(Guengerich, 1999; Nelson et al., 1996; 
Nebert and Russell, 2002). Human 
CYP3A4 is expressed in the prostate, 
breast, gut, colon and small intestine. How-
ever, its expression is most abundant in the 
liver which accounts for 30 % of the total 
CYP protein content (Guengerich, 1999; 
Lown et al., 1997; Shimada et al., 1994; 
Watkins et al., 1987). CYP3A4 plays an 
important role in the oxidation of both tes-
tosterone and estrogen. Activity of 
CYP3A4 can be inhibited or induced by 
drugs, herbs, pesticides, and carcinogens. 
Individual variation in CYP3A4 levels may 
play a role in breast and prostate carcino-
genesis through modulation of sex hormone 
metabolite levels. Alternatively, CYP3A4 
can be involved in bioactivation of exoge-
nous carcinogens. It has been shown that 
CYP3A4 is involved in activation of many 
environmental carcinogens. These include 
polycyclic aromatic hydrocarbons, hetero-
cyclic amines, aflatoxin B1, and nitrosa-
mines (Guengerich and Shimada, 1991; 
Patten et al., 1997; Shimada et al., 1994). 
Furthermore, ingestion of polycyclic aro-
matic hydrocarbons and heterocyclic 
amines, and their metabolism mediated by 
CYP3A4 has been shown to result in the 
formation of carcinogen DNA adducts in 
mammary tissues (Lightfoot et al., 2000). 
It has been hypothesized that alcoholic 
beverages, particularly red wine, offer extra 
cardiovascular protection due to their rich 
content of antioxidant flavonoid com-
pounds. Many flavonoids, such as querce-
tin, resveratrol and naringenin, have been 
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shown to alter the activity of CYP enzymes 
(Chan and Delucchi, 2000; Niestroy et al., 
2012). This effect could also be associated 
with a protective property against cancer. 
One target of the chemopreventive effect of 
naturally occurring flavonoids, such as 
grape constituents, could be inhibition of 
xenobiotic metabolizing phase I enzymes, 
i.e., CYP. Alternatively, it could be the in-
duction of phase II conjugation enzymes, 
such as UDP-glucuronosyltransferase and 
glutathione S-transferase, that are responsi-
ble for the detoxification of carcinogens. 
Among the main human CYPs, CYP1A1 
and CYP1A2 isoforms are involved in the 
activation of many procarcinogens; includ-
ing polycylic aromatic hydrocarbons, poly-
cyclic amines and aflatoxin B1 (Gonzalez 
and Gelboin, 1994). Resveratrol, a phyto-
alexin present in grapes, has been demon-
strated to be an aryl hydrocarbon receptor 
antagonist which inhibits the induction of 
the CYP1A1 enzyme (Chan and Delucchi, 
2000). CYP2E1 is responsible for the acti-
vation of volatile organic solvents and pre-
carcinogenic N-nitrosamines (Gonzalez et 
al., 1992, Yang et al., 2001; Zhou et al., 
2003). Human CYP3A4 activates aflatoxin 
B1 and the biotransformation of many clin-
ically used drugs (Gonzalez, 1992). More-
over, it has been shown that resveratrol in-
activated CYP3A4 in a time- and NADPH-
dependent manner (Chan and Delucchi, 
2000; Chan et al., 1998). The data suggest 
that resveratrol is an effective mechanism-
based inactivator of CYP3A4. 
From the above information, it clearly 
shows that developed countries recognize 
and value the importance of research on 
complementary alternative medicines, in-
cluding herbal medicines. This is the case 
especially in the USA and UK where there 
are established research funding agencies, 
such as the Office of Dietary Supplements 
(ODS) under the National Institutes of 
Health (NIH) and the “Prince of Wales 
Foundation for Integrated Health”, respec-
tively (The Office of Dietary Supplements 
website, Ernst et al., 2006). These empha-
size the relevance and clinical importance 
of pursuing research on herbal medicines. 
 
Mechanisms of herbal drug interactions: 
general considerations 
Like drug-drug interactions, herbal drug 
interactions result from the same principles. 
These principles are based on the same 
pharmacokinetic (i.e. changes of plasma 
drug concentration) and pharmacodynamic 
(i.e. drugs interacting at receptors) interac-
tions. The currently recognized pharmaco-
kinetic interactions between clinical drugs 
and herbs or herbal dietary supplements in-
dicate that a number of herbs, most remark-
ably St. John’s wort, can alter the plasma 
concentration of different conventional 
medicines metabolized by CYP, and/or are 
transported by P-gp (Izzo, 2012). P-gp is 
presented in the intestine, liver and kidney; 
it performs an important role in the absorp-
tion, distribution, or excretion of drugs. P-
gp appears to limit the cellular transport 
from intestinal lumen into epithelial cells 
and also enhances the excretion of drugs via 
hepatocytes and renal tubules into the adja-
cent luminal space. 
Many probe drugs have been used to as-
sess potential effects of herbs on the activi-
ty of a specific CYP enzyme. These probe 
drugs include midazolam, alprazolam, nife-
dipine (CYP3A4); debrisoquine, dextrome-
thorphan (CYP2D6); chlorzoxazone 
(CYP2E1); tolbutamide, diclofenac and 
flurbiprofen (CYP2C9); caffeine, tizanidine 
(CYP1A2); and omeprazole (CYP2C19). 
Fexofenadine, digoxin and talinolol have 
been extensively used in pharmacokinetic 
studies as P-gp substrates (Izzo, 2012). Po-
lymorphisms in the genes for CYP enzymes 
and P-gp may influence the interactions 
mediated through these pathways (Lei et 
al., 2009a). Pharmacodynamic-based inter-
actions between herbs and drugs have been 
less investigated. However, the outcomes of 
pharmacodynamic interactions may be ei-
ther additive or synergetic (i.e. the herbal 
medicines potentiate the pharmacologi-
cal/toxicological action of conventional 
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drugs) or antagonistic (i.e. the herbal medi-
cines reduce the efficacy of the drugs). 
Warfarin and herbal interactions are a clas-
sical example of pharmacodynamic interac-
tions. Theoretically, augmented anticoagu-
lant effects could be likely when warfarin is 
administered concomitantly with coumarin-
containing herbs (some plant coumarins 
exert anticoagulant effects) or with anti-
platelet herbs (Izzo, 2012). On the other 
hand, vitamin K-containing herbs can an-
tagonize the effect of warfarin (the action of 
warfarin is due to its ability to antagonize 
the cofactor function of vitamin K). 
A number of recently published review 
articles have comprehensively written and 
exclusively drawn attention to the mecha-
nisms of herbal drug interactions (Colalto, 
2010; Izzo, 2012; Tomlinson et al., 2008; 
Zhou et al., 2004, 2010; Zhang et al., 2009). 
They have provided evidence of herbs that 
can modify CYP or P-glycoprotein. 
 
CYP mediated herbal drug interactions: 
evidence in humans 
Evidence is emerging that particular 
herbs and herbal medicines may contain 
specific phytochemicals which can modu-
late the activity of drug metabolizing en-
zymes CYP and drug transporting protein, 
P-glycoprotein (P-gp). These modulations 
may lead to potential interaction between 
herbal medicines and prescription drugs. 
This review will focus on important herbal 
drug interactions having clinical relevance 
and discuss the mechanism of drug interac-
tions which is mediated by CYP enzymes. 
Some interactions mainly involved with 
function of P-gp are omitted, but may be 
mentioned. Studies in animals are generally 
excluded because of the marked species, 
which makes extrapolation of such results 
to humans difficult (European medicines 
Agency, 2013; Hermann and von Richter, 
2012). Herbal drug interactions caused by 
pharmacodynamic mechanisms including 
partly cover toxicities, while not less im-
portant, are outside the scope of this review 
article. Nevertheless, these have been re-
viewed elsewhere (Izzo and Ernst, 2009; 
Johne and Roots, 2005). 
 
Echinacea 
Echinacea is a genus of herbaceous 
flowering plants (purple coneflowers), and 
belongs to Asteraceae family. It comprises 
of nine species, which are native and en-
demic to eastern and central North Ameri-
ca. Marketed preparations of Echinacea 
arise from underground as well as aerial 
parts of three different species (E. pur-
purea, E. angustifolia, E. pallida), whereby 
the majority (i.e., about 80 %) of the pro-
ducts are based on E. purpurea. Due to its 
immunostimulant properties, echinacea is 
commonly used for the prevention and 
treatment of acute virus infections of the 
upper respiratory tract, such as the common 
cold and influenza (Capasso et al., 2008; 
Ernst et al., 2006, 2008). Recommended 
daily doses of echinacea products vary 
broadly depending on the formulation and 
content of the product. Usually daily doses 
of echinacea for adults range between 900 
to 1000 mg, to be taken in 3 to 4 divided 
doses. 
Echinacea is considered to be one of the 
safest herbal medicines, with few reported 
adverse effects and very few reports of in 
vivo drug interactions. Echinacea seems to 
cause no serious risk for drug interactions 
in humans (Izzo, 2012). No verifiable case 
reports of herbal drug interactions with any 
echinacea product have been published to 
date. The effect of echinacea (E. purpurea 
root) on specific CYP activities in humans 
was evaluated by using a single dose ad-
ministration of the CYP probe drugs in 12 
healthy subjects (Gorski et al., 2004). These 
CYP probes included caffeine (CYP1A2), 
tolbutamide (CYP2C9), dextromethorphan 
(CYP2D6), and midazolam (hepatic and 
intestinal CYP3A4). The probe drugs were 
administered before and after a short course 
of Echinacea [E. purpurea root extract 
400 mg, 4 times daily (= 1600 mg/day) for 
8 days], and respective plasma concentra-
tion-time profiles of the probe drugs were 
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determined. In this study, it was found that 
echinacea dosing significantly decreased 
the oral clearance of the CYP1A2 probe 
caffeine by 27 % (Gorski et al., 2004), indi-
cating inhibition of in vivo CYP1A2 cata-
lytic activity. Theophylline is a widely pre-
scribed CYP1A2 drug that has a narrow 
therapeutic window. Therefore modest 
changes of 20 % in clearance of theophyl-
line are considered to be clinically signifi-
cant (Gorski et al., 2004). There was con-
siderable inter-individual variability in this 
interaction, with 2 individuals (out of 12 
subjects) presenting a greater than 50 % 
reduction in caffeine oral clearance (Gorski 
et al., 2004). The co-administration of 
echinacea and theophylline may give rise to 
an increased incidence of toxicity develop-
ing from increased plasma theophylline 
concentrations. Other CYP1A2-metaboliz-
ed drugs which have adverse effect con-
cerns, such as clozapine, tacrine, and cyclo-
benzaprine, may be influenced by taking 
echinacea concomitantly (Gorski et al., 
2004). 
Echinacea dosing also significantly re-
duced (average by 11 %) the oral clearance 
and enhanced the systemic exposure of tol-
butamide (Gorski et al., 2004). This indi-
cates that the in vivo hepatic CYP2C9 activ-
ity was slightly inhibited by echinacea. 
However, the maximum plasma tolbutam-
ide concentration was not significantly 
modified by echinacea. These results 
showed a minor change in the pharmacoki-
netics of tolbutamide which is mainly me-
tabolized by CYP2C9. The observed mag-
nitude of changes in tolbutamide pharma-
cokinetic parameters, though statistically 
significant, is most likely lack clinical im-
portance with this echinacea product. Thus 
it suggests that co-administration of echina-
cea has no considerable effect on the activi-
ty of CYP2C9 enzyme (Gorski et al., 2004). 
However, the co-administration of echina-
cea with warfarin, a substrate known to be 
metabolized by multiple CYP enzymes in-
cluding CYP2C9 and CYP3A4 (Abernethy 
et al., 1991; Rettie et al., 1992), may result 
in variable responses from a decrease in 
efficacy due to CYP3A4 induction to tox-
icity as a result of CYP2C9 inhibition to no 
effect (offsetting changes). Gorski and co-
workers (Gorski et al., 2004) commented 
that the co-administration of other echina-
cea products that differ in phytochemical 
content to the brand they studied (E. pur-
purea root, Nature's Bounty) with CYP2C9 
substrates having a narrow therapeutic in-
dex such as phenytoin and warfarin may 
require to be cautiously monitored. 
In the same study, it was also shown 
that echinacea co-administration did not 
significantly affect the pharmacokinetic pa-
rameters (i.e., AUC0-∞, oral clearance, t1/2) 
of the CYP2D6 probe dextromethorphan 
(Gorski et al., 2004). This suggested that 
co-administration of echinacea does not al-
ter the metabolism and pharmacokinetics of 
drugs metabolized by CYP2D6.  
The systemic clearance of intravenously 
administered CYP3A4 probe midazolam 
was significantly enhanced by 42 %, and 
there was a corresponding significant de-
crease in mean AUC0-∞ of 23 % (Gorski et 
al., 2004). Collectively it indicates that he-
patic CYP3A4 activity was increased. On 
the other hand, the oral clearance and the 
AUC0-∞ after oral midazolam dosing were 
not significantly changed by echinacea co-
administration. Nevertheless, the mean ab-
solute oral bioavailability of midazolam 
was increased from 24 % to 36 % (i.e., by 
50 %). This is consistent with the inhibition 
of intestinal CYP3A4 by echinacea. The 
distinction effects of echinacea on intestinal 
and hepatic CYP3A4 activity may possibly 
be due to a diversity of mechanisms. These 
include, for example, locally acting 
CYP3A4 inhibiting constituents of echina-
cea that do not become systemically availa-
ble, or fast absorption of CYP3A4 inducing 
constituents of echinacea, thus limiting in-
testinal exposure and intestinal CYP3A4 
induction (Gorski et al., 2004). Alternative-
ly, it may be due to a systemically formed 
metabolite of an echinacea’s constituent 
that is capable of inducing hepatic CYP3A4 
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but not intestinal CYP3A4. In spite of this, 
these mechanistic considerations remain 
hypothetical and warrant further research. 
A further study by Gurley and col-
leagues (Gurley et al., 2004) employed sin-
gle-time point phenotypic metabolic ratios 
to determine whether long-term supplemen-
tation of Echinacea purpurea affected 
CYP1A2, CYP2D6, CYP2E1, or CYP3A4 
activity. This clinical study was performed 
in 12 healthy volunteers. They were ran-
domly assigned to receive E. purpurea 
(800 mg twice a day, or 1600 mg daily) for 
28 days. Probe drug cocktails of midazolam 
(CYP3A4) and caffeine (CYP1A2), fol-
lowed 24 hours later by chlorzoxazone 
(CYP2E1) and debrisoquine (CYP2D6) 
were administered before (baseline) and at 
the end of echinacea supplementation. Ac-
tivities of CYP3A4, CYP1A2, CYP2E1, 
and CYP2D6 enzymes during pre-
supplementation and post-supplementation 
were assessed by use of 1-hydroxymida-
zolam/midazolam serum ratios (1-hour 
sample), paraxanthine/caffeine serum ratios 
(6-hour sample), 6-hydroxychlorzoxa-
zone/chlorzoxazone serum ratios (2-hour 
sample), and debrisoquine urinary recovery 
ratios (8-hour collection), respectively. In 
this study, high-dose E. purpurea given 
over 28 days did not significantly change 
the activities of CYP3A4, CYP2E1, and 
CYP2D6 as estimated by single timepoint 
metabolic ratios. The only appreciable al-
teration in mean phenotypic ratios appeared 
with 6-hour paraxanthine/caffeine values. 
Co-administration of Echinacea purpurea 
caused an approximately 13 % decrease in 
the ratio of paraxanthine/caffeine, this sug-
gested that there was a possible inhibitory 
effect of E. purpurea on CYP1A2 enzyme. 
This minor difference, however, was not 
statistically significant (P = 0.07), nor was 
it thought clinically relevant. This finding 
suggests that prolonged use of E. purpurea 
poses a minimal risk of producing 
CYP1A2-, CYP2D6-, CYP2E1-, or CYP-
3A4-mediated herbal drug interactions in 
humans. In respect to the effects of E. pur-
purea extract on CYP3A4 and CYP2D6, 
the findings of Gurley et al. (2004) are con-
sistent with those of Gorski et al. (2004). 
This consistency happened regardless of 
differences in the type of E. purpurea prod-
ucts used (root extract versus whole plant 
extract), duration of supplementation (8 
days versus 28 days), and CYP phenotype 
assessment methodologies (AUC versus 
single-time point phenotypic ratio). The 
lack of or little effect of E. purpurea sup-
plementation on human CYP2D6 was sup-
ported by a clinical study by Gurley et al. 
(2008b). The evidence has shown that sup-
plementation of a standardized E. purpurea 
extract (267 mg three times a day = 801 
mg/day, for 14 days) caused no significant 
inhibition of CYP2D6 in 16 healthy sub-
jects using debrisoquine as the CYP2D6 
probe.  
Taken together, the study showed that 
an 8-day treatment with relatively high dos-
es of E. purpurea root extract (i.e., 400 mg, 
four times daily = 1600 mg/day) displayed 
differential effects on the activity of various 
CYP enzymes. There were no alterations of 
CYP2D6 noted, negligible to modest inhi-
bition of CYP2C9, modest inhibition of 
CYP1A2, and differential (i.e., inductive/ 
inhibitory) effects on hepatic and intestinal 
CYP3A4. 
Although the observed mean effects on 
CYP1A2 and CYP2C9 activities were gen-
erally moderate, they displayed some more 
pronounced effect sizes in individual sub-
jects. Considering CYP-based Echinacea-
drug interactions of potential clinical signif-
icance, the study suggests that the bioavail-
ability of orally administered CYP3A4 sub-
strates with low oral bioavailability may be 
significantly increased by Echinacea co-
administration. Also the exposure to 
CYP1A2 and CYP2C9 substrates (e.g., the-
ophylline, clozapine) may be modestly in-
creased, at least in some individual sub-
jects. The observed effects of high doses of 
E. purpurea root extract on CYP1A2 and 
CYP2C9, however, are overall small. 
Therefore, this is unlikely to be of clinical 
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significance in clinical practice, unless 
drugs with a narrow therapeutic index are 
involved. These examples are theophylline 
in case of CYP1A2 and (S)-warfarin in case 
of CYP2C9. 
A clinical study was conducted in 16 
healthy volunteers received lopinavir-
ritonavir (400/100 mg) twice daily for 30 
days (Penzak et al., 2010) to determine the 
effect of Echinacea purpurea on the phar-
macokinetics of lopinavir-ritonavir, and on 
CYP3A4 and P-glycoprotein (P-gp) activity 
using the probe substrates midazolam, and 
fexofenadine, respectively. Echinacea pur-
purea extract was given in a dosage of 500 
mg three times daily, which they continued 
for four weeks, the first two weeks in com-
bination with lopinavir-ritonavir. The HIV 
protease inhibitor lopinavir is extensive me-
tabolized by CYP3A4, whereas ritonavir is 
a potent inhibitor of CYP3A4 and P-gp. Ri-
tonavir is combined with lopinavir to boost 
(i.e., increase) its systemic exposure. The 
results have shown that neither lopinavir 
nor ritonavir pharmacokinetics were signif-
icantly altered by 2 weeks of Echinacea co-
administration (Penzak et al., 2010). How-
ever, with respect to activity of CYP3A4, 
Echinacea co-administration considerably 
reduced AUC0–12h and increased oral 
clearance of midazolam, a CYP3A4 probe. 
These suggested that the Echinacea co-
administration induced CYP3A4 enzyme 
activity and this in turn increased the clear-
ance of midazolam (Penzak et al., 2010). 
Thus co-administration of Echinacea pur-
purea may cause moderate decrease in 
plasma concentrations of other CYP3A4 
substrates. 
The above finding was also supported 
by a study conducted by Moltó et al. (2011) 
in which they determined the potential of 
Echinacea purpurea to interact with the 
boosted protease inhibitor darunavir-
ritonavir in 15 HIV-infected patients. Pa-
tients were receiving antiretroviral therapy 
including darunavir-ritonavir (600/100 mg 
twice a day) for at least 4 weeks. E. pur-
purea root extract capsules (500 mg every 6 
h, for 14 days) were concomitantly given 
on top of their antiretroviral treatment. In 
general, supplementation of Echinacea 
purpurea did not affect the overall pharma-
cokinetics of darunavir and ritonavir, alt-
hough individual patients did show a de-
crease in darunavir concentrations (Moltó et 
al., 2011). While no dose adjustment is re-
quired, monitoring darunavir concentrations 
on an individual basis may give reassurance 
in this setting. Their findings with darunavir 
exposure was reduced in some individual 
patients by 30 to 40 % after E. purpurea 
supplementation, would be harmonious 
with the finding of a modest induction of 
hepatic CYP3A4 by echinacea administra-
tion previously reported by Gorski et al. 
(2004). This evidence would be further 
consistent with the assumption that low-
dose ritonavir (100 mg twice daily) might 
not efficiently inhibit hepatic CYP3A4 ac-
tivity in individual patients (Hermann and 
von Richter, 2012). 
Overall, the outcomes from both studies 
(Moltó et al., 2011; Penzak et al., 2010) re-
garding the noticed changes in CYP3A4 
activity is consistent for the effects of E. 
purpurea supplementation on a darunavir-
ritonavir combination. These studies relia-
bly suggest that E. purpurea co-admini-
stration is unlikely to considerably alter the 
pharmacokinetics of ritonavir-boosted pro-
tease inhibitors. This is most likely due to 
the presence of the potent CYP3A inhibitor 
ritonavir, but may be capable to moderately 
induce hepatic CYP3A activity.  
Abdul and colleagues (Abdul et al., 
2010) studied the pharmacokinetic and 
pharmacodynamic interactions of Echina-
cea with warfarin in 12 healthy subjects 
who received a single oral 25 mg dose of 
warfarin alone and after 2 weeks of pre-
treatment with high-dose Echinacea 
(1275 mg four times daily = 5100 mg/day). 
Pharmacodynamic parameters including the 
international normalized ratio (INR), plate-
let activity) and pharmacokinetic (warfarin 
enantiomer concentrations) end points were 
evaluated. The apparent oral clearance of 
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(S)-warfarin was found to be significantly 
higher during concomitant treatment with 
echinacea but this did not lead to a clinical-
ly significant change in INR. Because (S)-
warfarin is metabolized by CYP2C9 and 
CYP3A4, whereas (R)-warfarin is metabo-
lized by CYP3A4 and CYP1A2 (Wittkow-
sky, 2003), it was proposed that a 2-week 
treatment with high doses of echinacea (i.e., 
5100 mg/day) does not appreciably alter the 
activities of these CYP enzymes. Generally, 
the small extents of the effect observed are 
doubtful to be of clinical relevance. 
In summary, the existing in vivo evi-
dence reveals that echinacea products at 
recommended doses have little potential to 
produce clinically relevant or worrying me-
tabolism-based pharmacokinetic interac-
tions involving CYP1A2, CYP2C9, 
CYP2D6 and CYP2E1. Sequentially, there 
is reasonable clinical evidence suggesting 
that Echinacea products in fact have poten-
tial to moderately induce hepatic CYP3A4 
activity. However, at the same time Echina-
cea products also may inhibit the pre-
systemic (intestinal) metabolism of 
CYP3A4 drugs. As both mechanisms work 
against each other in terms of the net effects 
on the systemic exposure of CYP3A4 
drugs, the onset of each mechanism proba-
bly occurs at different times (i.e., onset of 
inhibition occurs faster than onset of induc-
tion), and also will vary in their extent of 
effect on specific substrate characteristics 
(e.g., oral bioavailability of CYP3A4 
drugs). General predictions on the clinical 
relevance of Echinacea and CYP3A4 drug 
interactions are complicated to generate. In 
spite of this, warning is advised when 
CYP3A4 drugs with low oral bioavailabil-
ity due to pronounced intestinal CYP3A4-
mediated metabolism (e.g. verapamil, cy-
closporine A and tacrolimus) or CYP3A4 
drugs with narrow therapeutic index, are 
co-administered with Echinacea supple-
mentation. There are no clinical studies ad-
dressing the potential impact of Echinacea 
products on other important metabolic 
pathways such as CYP2C19 and phase II 
metabolism (e.g. glucuronidation). 
 
Ginkgo biloba 
Leaves from the tree Ginkgo (Ginkgo 
biloba; family Ginkgoaceae) have been 
used for 4000 years to improve mentation 
and respiratory function (Philp, 2004). The 
Ginkgo tree, also known as maidenhair tree, 
is the surviving member of ancient family 
Ginkgoaceae, with no close living relatives. 
Ginkgo biloba is claimed to improve cere-
bral and peripheral blood flow. Currently 
available pharmaceutical products of Gink-
go biloba represent leave extracts. Ginkgo 
biloba extract contains two constituents: 
ﬂavonoids and terpenoids, which have anti-
oxidant properties (Kennedy et al., 2011; 
Pierre et al., 2008). Oral standardized dry 
extracts of Ginkgo biloba generally contain 
between 22-27 % flavones glycosides; 5-
7 % terpene lactones, and should contain 
not more than 5 ppm of ginkgolic acids, 
constituents with known allergic potency 
(Kressmann et al., 2002). Many studies 
have been conducted using EGb 761, a 
well-defined extract of Ginkgo biloba. 
Ginkgo biloba extract is widely used in 
some countries by patients with cognitive 
disorders such as memory decline with age-
ing and Alzheimer's disease. Early studies 
showed that the extract was superior to pla-
cebo in improving symptoms of dementia, 
and this has been confirmed by more recent 
research (Andrieu et al., 2003; Ihl, 2012). 
Standardized ginkgo biloba extract has a 
good safety profile, although some case re-
ports have suggested an increased risk of 
bleeding.  
Ginkgo biloba preparations may con-
vene appreciable anti-platelet effects that 
are evidently caused by various gink-
golides. Consequently, information from 
case reports or controlled trials revealed 
that Ginkgo biloba extract potentiates the 
effects of anti-coagulant or anti-platelet 
drugs such as warfarin (Bone, 2008; Vaes 
and Chyka, 2000). However, these interac-
tions are related to the pharmacodynamic 
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interactions. While they are clinically im-
portant, the pharmacodynamic interactions 
are outside the scope of the current review 
on CYP mediated herbal drug interactions. 
There were various studies showing the 
in vitro effects of Ginkgo biloba extracts or 
specific constituents to alter activities of 
CYP enzymes. However, these results were 
generally inconsistent. Overall, the obtained 
findings indicated no effect and either inhi-
bition or induction of various human CYP 
enzymes. Some reports found the effects of 
Ginkgo biloba extracts on CYP are concen-
tration-dependently (i.e. inhibition at low 
concentrations, induction at high concentra-
tions). In some studies, a substrate-
dependent fashion effects have been de-
scribed. Of note, the results derived from in 
vitro studies have been obtained in part at 
very high concentrations of the herb (Gink-
go biloba). Such concentrations are unlikely 
to be achieved in humans (in vivo) after 
recommended doses of Ginkgo biloba ex-
tracts. This particular aspect is considered 
to be a major disadvantage of in vitro stud-
ies. Together, the buildup of evidence from 
in vitro studies offers little guidance in the 
reliable prediction of relevant metabolic-
based Ginkgo biloba mediated drug interac-
tions in vivo (Hermann and von Richter, 
2012). 
Luckily, there are a number of clinical 
studies that have been carried out to deter-
mine the effects of Ginkgo biloba on many 
CYP isoforms and other drug metabolizing 
enzymes including phase II conjugations. 
These investigations mainly employed spe-
cific probe drugs as substrates for CYP en-
zymes in which it allows the identification 
and quantification of changes of specific 
CYP enzyme activity. Gurley et al. (2002) 
employed single-time point phenotypic 
metabolic ratios to determine whether long-
term supplementation of St. John’s wort, 
garlic oil, Panax ginseng, and Ginkgo bi-
loba affected CYP1A2, CYP2D6, CYP2E1, 
or CYP3A4 activity in healthy young vol-
unteers. Dosages of 60 mg Ginkgo biloba 
dietary supplements were given (four times 
daily) to 12 healthy subjects over 28 days. 
In this particular study, probe drug cocktails 
of caffeine, debrisoquine, chlorzoxazone, 
and midazolam were administered before 
and at the end of Ginkgo biloba supplemen-
tation. Activities of CYP1A2, 2D6, 2E1, 
and 3A4 were assessed by the use of par-
axanthine/caffeine serum ratios (6-hour 
sample), debrisoquine urinary recovery ra-
tios (8-hour collection), 6-hydroxychlorzo-
xazone/chlorzoxazone se-rum ratios (2-hour 
sample), and 1-hydroxymidazolam/mida-
zolam serum ratios (1-hour sample), respec-
tively. Comparisons of pre-treatment and 
post-treatment ratios revealed that Ginkgo 
biloba did not cause any appreciable change 
of CYP1A2, 2D6 and 3A4 activity. In con-
trast, Ginkgo biloba appeared to moderately 
increase the activity of CYP2E1 by 23 %, 
even though this effect was not statistically 
significant (Gurley et al., 2002). This sug-
gests a trend of CYP2E1 is being induced 
by Ginkgo biloba. A similar study was con-
ducted by the same group of researchers 
(Gurley et al., 2005a) but in 12 elderly sub-
jects, using the same Ginkgo biloba prod-
uct, dose and treatment duration, as well as 
the same CYP probe drugs. Surprisingly, 
Ginkgo biloba had no significant effect on 
the activity of CYP1A2, 2D6, 2E1, and 
3A4 in this elderly subjects. Thus these re-
sults do not confirm the earlier observed 
trend regarding a moderate CYP2E1 induc-
tion (Gurley et al., 2005a). 
Lack of effect of Ginkgo biloba on the 
activity of CYP2D6 and CYP3A4 was sup-
ported by the evidence derived from a clini-
cal study conducted by Markowitz and col-
leagues (Markowitz et al., 2003a). This 
study was similar in nature to those previ-
ously conducted by Gurley et al. (2005a). 
However, they assessed the influence of 
standardized Ginkgo biloba extract on the 
activity of CYP2D6 and CYP3A4 in 
healthy young adults, instead of elderly 
volunteers as used in Gurley and co-
workers’ study (Gurley et al., 2005a). In the 
trial by Markowitz et al. (2003a), dextrome-
thorphan (CYP2D6 activity) and alprazo-
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lam (CYP3A4 activity) were employed as 
specific substrates for the CYPs of interest. 
These probe drugs were co-administered 
orally at baseline, and following treatment 
with Ginkgo biloba extract (120 mg twice a 
day) for 14 days. There were no statistically 
significant differences between baseline 
and post-Ginkgo biloba treatment on dex-
tromethorphan metabolic ratios. This indi-
cated a lack of Ginkgo biloba effect on 
CYP2D6 activity. Regarding the CYP3A4 
activity, a statistically significant decrease 
in the AUC of alprazolam was detected af-
ter treatment with Ginkgo biloba. The 
AUCs were decreased by 17 %, an amount 
that could be clinically significant for drugs 
with narrow therapeutic indices. However, 
when the effects of Ginkgo biloba are com-
pared with synthetic medications known to 
induce alprazolam metabolism such as car-
bamazepine and rifampin, the magnitude of 
Ginkgo biloba effects were quite small 
(Markowitz et al., 2003a). Therefore, the 
authors concluded that standardized ex-
tracts of Ginkgo biloba, when taken in 
normally recommended doses, do not sig-
nificantly alter the activity of human 
CYP2D6 and CYP3A4 enzymes. Thus, 
there appears to be little likelihood of sig-
nificant herbal drug interactions between 
Ginkgo biloba and drugs predominantly 
metabolized by CYP2D6 or CYP3A4 
isoforms (Markowitz et al., 2003a). 
In addition, the effects of Ginkgo biloba 
supplementation (90 mg/day for 30 days) 
on the steady-state plasma concentration of 
donepezil were examined (Yasui-Furukori 
et al., 2004) in elderly patients with Alz-
heimer's disease; the patients received 
donepezil 5 mg/day. Donepezil, the 'first-
line' cholinesterase inhibitor, in the treat-
ment of Alzheimer's disease, is metabolized 
by CYP2D6 and CYP3A4 (Jann et al., 
2002). The results from this study demon-
strated that taking relatively low doses of 
Ginkgo biloba (90 mg/day) in elderly Alz-
heimerʼs Japanese patients did not alter the 
steady-state plasma concentrations of 
donepezil. This implies that daily doses of 
90 mg of Ginkgo biloba do not have signif-
icant inhibitory or inducing effects on the 
CYP2D6- and CYP3A4-mediated metabo-
lism of donepezil in the target population. 
This finding supports previous studies by 
Gurley et al. (2005a) and Markowitz et al. 
(2003a) in regard to the lack of interaction 
between Ginkgo biloba and drugs that are 
metabolized by CYP2D6 or CYP3A4. 
Robertson and coworkers (Robertson et 
al., 2008) also used a similar methodology 
to determine whether Ginkgo biloba extract 
causes any alterations in the activity of hu-
man CYP3A4. Midazolam was employed 
as a probe drug for human CYP3A4. Be-
sides midazolam, the investigators also 
used fexofenadine as a marker drug to mon-
itor the influence of Ginkgo biloba on the 
activity of drug transporter protein, P-
glycoprotein (P-gp). Effect of Ginkgo bi-
loba extract on pharmacokinetics of mid-
azolam and fexofenadine (after a single 
dose), and lopinavir’s pharmacokinetics at 
steady-state, in healthy subjects was as-
sessed before and after the subjects re-
ceived Ginkgo biloba at a dose of 120 mg, 
two times daily (for 4 weeks). Lopinavir, 
ritonavir, and fexofenadine exposures were 
not significantly affected by Ginkgo biloba 
co-administration, while total AUC and 
maximum plasma drug concentration 
(Cmax) of the CYP3A4 substrate midazo-
lam were both significantly lower post 
Ginkgo biloba supplementation, i.e. by 
34 % and 31 %, respectively, as compared 
to baseline. The apparent oral clearance of 
midazolam increased in 10 of 13 subjects 
studied post Ginkgo biloba supplementa-
tion. These results suggest that Ginkgo bi-
loba moderately induces CYP3A4 metabo-
lism. The authors commended that as the 
reductions in midazolam AUC and Cmax 
were similar, with no change in half-life of 
midazolam, it appears likely that the inter-
action occurred secondary to CYP3A4 in-
duction at the intestinal level (Robertson et 
al., 2008). However, it cannot be ruled out 
that hepatic induction of CYP3A4 may also 
have contributed. These findings obtained 
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from the study of Robertson et al. (2008) 
are in contrast with those previously report-
ed by Gurley et al. (2005a) who found that 
28 days of Ginkgo biloba extract (60 mg, 
four times daily) had no apparent effect on 
midazolam metabolism in 12 healthy sub-
jects. Robertson and co-authors (Robertson 
et al., 2008) thought that it is unlikely that 
the disparity in their findings is due to dif-
ferences in Ginkgo biloba extract formula-
tion, as the total daily dose of Ginkgo bi-
loba (240 mg/day) was the same in both 
studies and both products were standardized 
to the same flavonol glycoside and terpene 
lactone contents. To our knowledge, as 
herbal dietary supplements generally have 
problems with quality control aspects, in-
cluding Ginkgo biloba (Draves and Walker, 
2003; Foster et al., 2005; Haller et al., 
2004), thus the differences in the content of 
active ingredients, dissolution and absorp-
tion characteristics of the formulation used 
cannot be excluded.  
However, the two studies were different 
in their approach to assessing CYP3A4 
phenotype. Robertson and colleagues (Rob-
ertson et al., 2008) assessed CYP3A4 activ-
ity by determining midazolam AUC before 
and after 4 weeks of Ginkgo biloba extract 
administration. Whereas, in Gurley et al. 
(2005a) investigation, a 1-h post-dose 
plasma concentration ratio of 1-hydroxy-
midazolam/midazolam was used to assess 
human CYP3A4 activity. Use of this ratio 
to determine human CYP3A4 activity has 
produced inconsistent results in previous 
studies, perhaps caused by significant inter-
patient heterogeneity in the glucuronidation 
of 1-hydroxymidazolam. This can alter the 
1-hydroxymidazolam/midazolam ratio in-
dependent of CYP3A4-mediated metabo-
lism (Eap et al., 2004; Rogers et al., 2002; 
Streetman et al., 2000). Therefore, it has 
been suggested that using midazolam con-
centrations alone, as opposed to 1-hydro-
xymidazolam ratios, offers a more accurate 
assessment of CYP3A4 activity (Nafziger 
and Bertino, 2007; Penzak et al., 2008).  
Ginkgo biloba extract is also widely 
used as herbal dietary supplement in Japan. 
The effects of Ginkgo biloba extract on the 
pharmacokinetics and pharmacodynamics 
of nifedipine, a calcium-channel blocker, 
were studied using 8 healthy volunteers. 
Concurrent oral ingestion of Ginkgo biloba 
extract (240 mg/day) did not significantly 
affect any of the mean pharmacokinetic pa-
rameters of either nifedipine or its major 
metabolite dihydronifedipine (Yoshioka et 
al., 2004). However, unexpected observa-
tion was found in which the maximal plas-
ma nifedipine concentrations in 2 subjects 
were approximately doubled during these 
subjects were taking Ginkgo biloba extract 
concomitantly with nifedipine. The authors 
also observed that these 2 subjects had ex-
perienced more severe and longer-lasting 
headaches during Ginkgo biloba extract 
phase than the control phase (Yoshioka et 
al., 2004). The mean heart rate after oral 
administration of nifedipine with Ginkgo 
biloba extract had a tendency to be faster 
than that without Ginkgo biloba extract at 
every time point. The adverse drug reac-
tions observed were coincident with the ab-
normally high maximum plasma nifedipine 
concentrations in these particular two sub-
jects. From this it was concluded that Gink-
go biloba extract and nifedipine should not 
be simultaneously administered, and careful 
monitoring is necessary when nifedipine 
and Ginkgo biloba extract need to be taken 
together in humans (Yoshioka et al., 2004). 
Although the authors emphasized the find-
ing of abnormally increased maximal plas-
ma nifedipine concentrations in two sub-
jects upon co-administration of Ginkgo bi-
loba extract, they also discussed possible 
underlying mechanisms. Nifedipine has a 
well recognized pharmacokinetic variability 
this together with the overall study results 
implies the absence of any Ginkgo biloba 
effects in respect of the total nifedipine ex-
posure (i.e., AUC). This supports the hy-
pothesis that there is no systematic effect 
due to Ginkgo biloba on the bioavailability 
of nifedipine. As nifedipine is an antihyper-
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tensive drug known to be primarily metabo-
lized by CYP3A4 (Bailey et al., 2013; Ne-
bert and Russell, 2002), this interpretation 
would be in agreement with previous re-
ports from other investigators showing lack 
of effect of Ginkgo biloba on metabolism 
and pharmacokinetics of CYP3A4 metabo-
lized drugs. 
Effects of a higher daily dose (360 mg/ 
day, for 28 days) of Ginkgo biloba extract 
on CYP3A4 and CYP2C9, were evaluated 
(Uchida et al., 2006). CYP3A4 probe (mid-
azolam) and CYP2C9 probe (tolbutamide) 
were orally administered as a single dose to 
10 healthy volunteers before and after in-
take of Ginkgo biloba extract. AUC(0-
infinity) for midazolam was significantly 
increased (25 %) by Ginkgo biloba extract 
intake and oral clearance was significantly 
decreased (26 %). These results suggested 
that Ginkgo biloba extract may inhibit the 
activity of CYP3A4, therefore it increased 
exposure to drugs cleared by CYP3A4 
(Uchida et al., 2006). Furthermore, these 
researchers examined the potential interac-
tion between Ginkgo biloba extract and 
CYP2C9-metabolized drugs using tolbut-
amide as a CYP2C9 probe. Their results 
have shown that the AUC(0-infinity) for 
tolbutamide after Ginkgo biloba extract in-
take was slightly but significantly (16 %) 
lower than that before Ginkgo biloba ex-
tract intake. Co-administration of Ginkgo 
biloba extract with tolbutamide tended to 
reduce AUC(0-2h) of blood glucose-
lowering effect of tolbutamide. Therefore, 
the authors suggested that the combination 
of Ginkgo biloba extract and drugs should 
be cautiously in terms of the potential inter-
actions, especially in elderly patients or pa-
tients treated with drugs exerting relatively 
narrow therapeutic windows (Uchida et al., 
2006). When considering the magnitude of 
changes in pharmacokinetic parameters of 
CYP3A4 and CYP2C9-metabolized drugs 
caused by taking Ginkgo biloba extract 
concomitantly with the drugs, it revealed a 
minor alteration in the activities of these 
CYP enzymes of interest. This minor 
CYP2C9 induction and some inhibition of 
intestinal CYP3A4 were achieved with su-
pra-therapeutic doses (360 mg/day) of 
Ginkgo biloba extract. The study results of 
drug interactions with Ginkgo biloba ex-
tract on CYP3A4- and CYP2C9 metaboli-
cally cleared drugs show minimal effect 
due to Ginkgo biloba extract (Hermann and 
von Richter, 2012). Thus, this is in agree-
ment with reports from other studies that 
suggested there was no effect by Ginkgo 
biloba extract on the activity of these en-
zymes at recommended doses. 
Zuo et al. (2010) employed diazepam as 
a probe substrate of CYP2C19 and 
CYP3A4 to determine the effects of Ginkgo 
biloba extract on the pharmacokinetics of 
diazepam. A single oral dose (10 mg) of 
diazepam was given either alone or con-
comitantly with oral Ginkgo biloba extract 
(120 mg twice daily) for 28 days to 12 
healthy volunteers. They found that total 
AUC for diazepam and the main metabolite 
N-desmethyldiazepam were essentially un-
altered. This data indicate that the disposi-
tion of CYP2C19 and CYP3A4 substrates 
is unlikely to be markedly modified by re-
commended doses of Ginkgo biloba prod-
ucts (Zuo et al., 2010).  
The effect of Ginkgo biloba extract on 
the pharmacokinetics and pharmacodynam-
ics of warfarin was investigated in 12 
healthy subjects (Jiang et al., 2005). A sin-
gle 25-mg dose of warfarin (Coumadin™) 
was given to each subject with and without 
pretreatment with multiple doses of Ginkgo 
biloba for 1 week (Tavonin™; 40 mg three 
times a day = 120 mg/day). Dosing of 
Ginkgo biloba was continued for a further 
week after warfarin administration. S-war-
farin is mainly metabolized to S-7-hydroxy-
warfarin by CYP2C9, and R-warfarin is 
metabolized by CYP1A2 and CYP3A4. Us-
ing warfarin as a probe substrate, thereby 
allows for a separate mechanistic assess-
ment of any potential change of these meta-
bolic pathways by concomitant Ginkgo bi-
loba treatment. Co-administration of rec-
ommended doses of a commonly used 
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herbal supplement, Ginkgo biloba did not 
affect the pharmacokinetics and the phar-
macodynamics of warfarin enantiomers af-
ter a single dose of warfarin in healthy male 
subjects (Jiang et al., 2005). Also, Ginkgo 
biloba did not affect blood clotting status or 
platelet aggregation.  
In addition, the effect of Ginkgo biloba 
on the activity of CYP2C9, the isoform re-
sponsible for S-warfarin clearance, was as-
sessed in 11 healthy volunteers who re-
ceived single 100-mg doses of the non-
steroidal anti-inflammatory drug (NSAID) 
flurbiprofen, a probe substrate for CYP2C9 
(Greenblatt et al., 2006a). Subjects also re-
ceived either a standardized Ginkgo biloba 
leaf preparation (Ginkgold, 3 doses of 
120 mg) or matching placebo in a random-
ized crossover study. The study showed that 
pretreatment of healthy subjects with usual 
clinical doses of Ginkgo biloba has no de-
tectable effect on the pharmacokinetics of a 
single dose of flurbiprofen or on the appar-
ent extent of formation of the principal hy-
droxylated metabolite. The findings suggest 
that short-term exposure to Ginkgo biloba 
does not inhibit CYP2C9 activity in vivo 
(Greenblatt et al., 2006a). As the study in-
volved only short-term exposure to Ginkgo 
biloba, it was not intended to capture possi-
ble CYP2C9 induction that could occur 
with long-term treatment. The results con-
firm previous controlled clinical studies 
showing no effect of ginkgo on the pharma-
cokinetics or pharmacodynamics of warfa-
rin which is metabolized by CYP2C9. This 
finding is also supported by an in vivo study 
conducted by Mohutsky et al. (2006). They 
carried out two pharmacokinetic studies in 
healthy subjects using tolbutamide and di-
clofenac as probe substrates of CYP2C9. 
They found there were no interactions be-
tween Ginkgo biloba extract and these 
CYP2C9 probe substrates in vivo as 
demonstrated by the lack of effect on the 
steady-state pharmacokinetics of diclofenac 
and the urinary metabolic ratio of tolbutam-
ide (Mohutsky et al., 2006). This evidence 
seems to be contradictory to a number of 
case reports having documented possible 
interactions between Ginkgo biloba and 
warfarin (Fugh-Berman and Ernst, 2001; 
Izzo and Ernst, 2001). Such an interaction 
is mostly relevant to elderly patients on an-
ticoagulant therapy. However, this interac-
tion appears to be attributable to the inhibi-
tion of platelet activating factor by various 
ginkgolides (Zhu et al., 1999). That is me-
diated by a pharmacodynamic mechanism. 
Explanation by a CYP-mediated metabo-
lism for the Ginkgo biloba and warfarin in-
teraction looks less possible based on the 
clinical data described above (Gurley et al., 
2002; Jiang et al., 2005). 
Yin and coworkers (Yin et al., 2004) 
investigated the potential herbal drug inter-
action between Ginkgo biloba and omepra-
zole, a widely used CYP2C19 substrate, in 
subjects with different CYP2C19 geno-
types. Eighteen healthy Chinese subjects 
previously genotyped for CYP2C19 were 
studied. All subjects received a single 
omeprazole 40 mg at baseline and then at 
the end of a 12-day treatment period with 
Ginkgo biloba (140 mg, twice a day). Mul-
tiple blood samples were collected over 
12 h, and 24 h urine was collected post 
omeprazole dosing. Plasma concentrations 
of omeprazole and its metabolite omepra-
zole sulfone were significantly decreased, 
and 5-hydroxyomeprazole significantly in-
creased following Ginkgo biloba admin-
istration in comparison to baseline. A sig-
nificant decrease in the ratio of AUC of 
omeprazole to 5-hydroxyomeprazole was 
observed in the homozygous extensive me-
tabolizers, heterozygous extensive metabo-
lizers, and poor metabolizers, respectively. 
The decrease was greater in poor metabo-
lizers than extensive metabolizers. No sig-
nificant changes in the AUC ratios of 
omeprazole to omeprazole sulfone were 
observed. Renal clearance of 5-hydroxy-
omeprazole was significantly decreased af-
ter Ginkgo biloba, but the change was not 
significantly different among the three gen-
otype groups. Their results show that Gink-
go biloba can induce omeprazole hydro-
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xylation in a CYP2C19 genotype-depend-
ent manner and concurrently reduce the re-
nal clearance of 5-hydroxyomeprazole. Co-
administration of Ginkgo biloba with ome-
prazole or other CYP2C19 substrates may 
significantly reduce their effects, but further 
studies are warranted (Yin et al., 2004). 
Possible effects of Ginkgo biloba as an 
inducer of CYP2C19 on single-dose phar-
macokinetics of voriconazole were exam-
ined in 14 Chinese volunteers genotyped as 
either CYP2C19 extensive or poor metabo-
lizers (Lei et al., 2009b). Pharmacokinetics 
of oral voriconazole 200 mg after admin-
istration of Ginkgo biloba 120 mg twice 
daily for 12 days were determined for up to 
24 hours in a 2-phase randomized crossover 
study. For extensive metabolizers, the me-
dian value for voriconazole’s AUC(0 to in-
finity) after administration of voriconazole 
alone was not significantly different from 
that after voriconazole with Ginkgo biloba 
(P > 0.05). The other pharmacokinetic pa-
rameters of voriconazole such as time to 
reach maximum concentration, half-life, 
and apparent clearance also did not change 
significantly for extensive metabolizers in 
the presence of Ginkgo biloba. Pharmaco-
kinetic parameters followed a similar pat-
tern for poor metabolizers. The authors 
concluded that 12 days of treatment with 
Ginkgo biloba did not significantly alter the 
pharmacokinetics of voriconazole in either 
CYP2C19 extensive or poor metabolizers. 
Thus, the pharmacokinetic interactions be-
tween voriconazole and Ginkgo biloba may 
have limited clinical significance. Based on 
these results, it can be assumed that - even 
at the highest recommended doses - Ginkgo 
biloba-mediated CYP2C19-based pharma-
cokinetic drug interactions appear to be 
light and may have restricted clinical signif-
icance. 
In recent study, cocktail phenotyping 
design was used to evaluate the metabolic 
drug interaction profile of Ginkgo biloba 
extract EGb 761® with respect to the ac-
tivities of major CYP enzymes (Zadoyan et 
al., 2012). These included CYP1A2, 
CYP2C9, CYP2C19, CYP2D6, and CYP-
3A4. In random order, the following pre-
treatments were administered to 18 healthy 
men and women for 8 days each: placebo 
twice daily, EGb 761® 120 mg twice daily, 
and EGb 761® 240 mg in the morning and 
placebo in the evening. The phenotyping 
cocktail was orally administered before and 
after the EGb 761®/placebo pretreatment 
periods. CYP probe drugs and metrics used 
were: tolbutamide (CYP2C9, plasma con-
centration 24-h postdose), omeprazole 
(CYP2C19, omeprazole/5-hydroxy omepra-
zole plasma ratio 3-h postdose), dextrome-
thorphan (CYP2D6, dextromethorphan/ 
dextrorphan plasma ratio 3-h postdose), and 
midazolam (CYP3A4, plasma concentra-
tion 6-h postdose). EGb 761®/placebo rati-
os for phenotyping metrics were close to 
unity for all CYP enzymes studied, except 
for CYP2C9, which may suggest a weak 
trend towards induction of these CYP2C 
family enzymes (Zadoyan et al., 2012). 
Their data obviously show that even a rela-
tively high dose of 240 mg daily doses of 
EGb 761® extract, it has no inhibitory ef-
fect towards CYP1A2, CYP2C9, 
CYP2C19, CYP2D6, and CYP3A4, irre-
spective whether the product is given once 
or twice daily (Zadoyan et al., 2012). The 
study also demonstrates that EGb 761® ex-
tract does not induce the activity of human 
CYP1A2, CYP2D6, and CYP3A4 enzymes. 
Supplementation of Ginkgo biloba (EGb 
761® extract) may present a weak induc-
tion of CYP2C9 and CYP2C19 enzymes, 
which, however, seems very small to be of 
clinical relevance (Hermann and von Rich-
ter, 2012; Zadoyan et al., 2012). 
Together, the existing evidence reveals 
that taking Ginkgo biloba extract at re-
commended doses up to daily doses of 
240 mg do not have substantial or clinically 
meaningful effects on the activity of human 
CYP enzymes including CYP1A2, CYP-
2C9, CYP2C19, CYP2D6, CYP2E1, and 
CYP3A4. Apparently, CYP2C19 enzyme 
was shown to be moderately inducible by 
Ginkgo biloba extract products. This effect 
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appears to occur at the highest recommend-
ed dose of level of 240 mg/day (Lei et al., 
2009a). Also the induction effect on 
CYP2C19 may become somewhat more 
prominent with increasing doses of Ginkgo 
biloba extract (Yin et al., 2004). Further-
more the extent of this induction effect 
might depend on the individual CYP2C19 
genotype of subjects (Yin et al., 2004) and 
possibly on characteristics of that particular 
CYP substrate. The existing evidence on 
this issue appears not to be consistent and 
further investigation is warranted. 
Findings on pharmacokinetic alterations 
of CYP3A4 due to taking Ginkgo biloba 
concomitantly are not entirely consistent. 
Some studies suggested the possibility of 
presystemic induction of CYP3A4 with a 
high-dose treatment of Ginkgo biloba, 
whereas some data suggest CYP3A4 inhibi-
tion. For example, a study by Robertson et 
al. (2008) showed a significant induction 
effect of Ginkgo biloba extract on CYP3A4 
enzyme, but the extent of enzyme induction 
(approximately 30 % reduction in AUC of 
midazolam) was relatively small as com-
pared to a large inter-individual variation in 
CYP3A4 activity observed in humans 
(Watkins, 1994; Wrighton et al., 1993; 
Zhang et al., 1997). Thus the overall extent 
of CYP3A4-related effects produced by 
Ginkgo biloba are usually weak and doubt-
ful to be of clinical relevance, unless for 
CYP3A4 drugs with a narrow therapeutic 
index are involved. 
The evidence described previously also 
suggests that standard daily dose of Ginkgo 
biloba extract has no appreciable effect on 
the activity of two important drug metabo-
lizing enzymes, human CYP3A4 and 
CYP2D6. Human CYP2D6 enzyme is in-
volved in the metabolism of approximately 
25 % of drugs on the market (Zhou, 2009). 
It metabolizes several clinically used drugs 
such as antidepressants (imipramine, 
desipramine and fluoxetine), cardiovascular 
drugs especially antiarrhythmic drugs (en-
cainide, flecainide), opioid analgesics 
(morphine, codeine and tramadol) in which 
some have a narrow therapeutic index. Also 
approximately 50 % of clinically used 
drugs are metabolized by human CYP3A4. 
Therefore, lack of drug interaction (via 
CYP metabolism) between majority of clin-
ically used drugs metabolized by CYP2D6 
and CYP3A4, and Ginkgo biloba provides a 
safety for patients who currently take this 
herbal supplement.  
Ginkgo biloba happen to be at this time, 
the second best studied natural health prod-
uct, in regards to the clinical investigation 
of its metabolic and transporter-based 
pharmacokinetic drug interaction potential 
(Hermann and von Richter, 2012). The 
available array of published mechanistic 
herbal drug interaction studies permits rea-
sonable interpretations on the particular 
drug metabolizing enzyme and transporter 
effects of Ginkgo biloba products in vivo. 
The information derived from these studies 
is largely consistent, with some minor dis-
agreements that may be accounted for dif-
ferences in study design, population stud-
ied, dose size, treatment durations, and per-
haps differences in the composition of 
products investigated (Hermann and von 
Richter, 2012). 
 
St. John’s wort 
St. John's wort (Hypericum perforatum 
L.; family Clusiaceae) is a popular medici-
nal herb used for the treatment of depres-
sion. Hypericum perforatum is a yellow-
flowering, perennial herb native to Europe 
which has been introduced to many temper-
ate areas of the world and grows wild in 
many meadows (Gurley et al., 2012). The 
common name comes from its traditional 
flowering and harvesting on 24th June, the 
birthday of John the Baptist (St. John's 
Day). St. John's wort is the most studied 
botanical dietary supplement in the world. 
With more than 2000 peer-reviewed articles 
published on its safety and efficacy (Gurley 
et al., 2012). Many clinical trials have 
shown antidepressive efficacy of St. John's 
wort superior to placebo and comparable to 
standard antidepressants but with fewer side 
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effects than conventional antidepressive 
agents (Linde et al., 2008). When used as a 
single agent, a risk/benefit ratio has made 
St. John's wort one of the most readily con-
sumed dietary supplements in the world.  
St. John's wort affects the pharmacoki-
netics of several drugs by inducing CYP 
isozymes, such as CYP3A4, CYP2C19, 
CYP2C9, and the drug transporter protein 
P-gp. This causes St. John's wort to be a 
highly problematic botanical with regard to 
CYP-mediated herbal drug interactions 
(Ang-Lee et al., 2001; Brazier and Levine, 
2003; Gurley and Hagan, 2003; Izzo and 
Ernst, 2001). St. John’s wort contains nu-
merous pharmacologically active com-
pounds, including hyperforin, hypericin, 
pseudohypericin, and flavonoids (e.g., 
quercetin, quercitrin and I3,II8-biapigenin). 
Hyperforin, the principal mediator of St. 
John’s wort antidepressive action, and is the 
main reason for St. John’s wort herbal drug 
interaction potential. Hyperforin is a good 
ligand for the pregnane xenobiotic receptor 
(PXR) and thus acts as a potent inducer of 
CYP3A4 and P-gp, the gene product of 
MDR1 (Moore et al., 2000; Watkins et al., 
2003). According to one estimate, hyperfor-
in is the most potent PXR activator discov-
ered to date. The clinical severity of St. 
John’s wort-drug interactions was first doc-
umented in 1999-2000 (Gurley et al., 
2005a). At that time, numerous clinics 
around the world reported that concomitant 
use of St. John’s wort and cyclosporine A 
produced remarkable reductions in blood 
levels of the immunosuppressant among 
organ transplant recipients resulting in graft 
rejection. Since that time, an overabun-
dance of clinical studies has investigated 
the effect of St. John’s wort on the pharma-
cokinetics of several medications (Gurley et 
al., 2005a). 
Clinical data revealed that St. John’s 
wort may cause both pharmacokinetic and 
pharmacodynamic drug interactions. Em-
ploying well-established probe drugs, a 
large number of clinical studies have con-
sistently demonstrated that St. John’s wort 
induced P-gp, a drug transporter protein. 
Co-administration of St. John’s wort also 
markedly induced human CYP3A4, 
CYP2E1 and CYP2C19 whereas it had no 
appreciable effect on CYP1A2, CYP2C9 
and CYP2D6 (Arold et al., 2005; Dresser et 
al., 2003; Hafner et al., 2010; Markowitz et 
al., 2003b; Roby et al., 2001; Wang et al., 
2001, 2004, 2009; Wenk et al., 2004; Xie et 
al., 2005).  
Induction of activity of CYP enzymes 
and P-gp is produced by hyperforin through 
activation of the PXR (Hall et al., 2003; 
Mai et al., 2004; Mueller et al., 2006). In-
terestingly, it has been reported that the 
CYP induction effect of St. John’s wort was 
dependent upon the active hyperforin con-
tent (Mai et al., 2004; Mueller et al., 2006, 
2009). Mai et al. (2004) found that co-
administration of cyclosporine A with the 
conventional St. John’s wort preparation 
contained high-hyperforin content (7 mg) to 
renal transplant patients led to the expected 
40 % to 60 % decrease in AUC, Ctrough, 
and Cmax values of cyclosporine A. This 
significant decrease in cyclosporine A’s 
AUC values caused by the interaction with 
St. John’s wort necessitated a substantial 
increase in cyclosporine A dose to maintain 
sufficient immunosuppression. In contrast, 
the St. John’s wort preparation contained 
with low-hyperforin content (0.1 mg) did 
not significantly affect cyclosporine A 
pharmacokinetics and did not require cyclo-
sporine A dose adjustments compared with 
baseline (Mai et al., 2004). The magnitude 
of CYP3A4 induction mediated by St. 
John’s wort correlated significantly with the 
content of hyperforin in the St. John’s wort 
extracts but not with the content of hyperi-
cin (Gödtel-Armbrust et al., 2007; Komoro-
ski et al., 2004; Mai et al., 2004).  
Interactions of St. John’s wort with an-
other immunosuppressant, tacrolimus 
(FK506), in renal transplant patients were 
also tested (Bolley et al., 2002). During 
long-term treatment with 2 mg/day of tacro-
limus, the blood trough levels of tacrolimus 
in the renal transplant patient had been sta-
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ble in a range from 6-10 mcg/L. The patient 
started a self-medication with St. John’s 
wort extract at a dosage of 600 mg per day 
because of a depressive mood disorder. Ap-
proximately a month later, tacrolimus 
trough levels decreased sharply to a mini-
mum level of 1.6 mcg/L during St. John’s 
wort co-administration (Bolley et al., 2002). 
A re-evaluation of the patient’s drug history 
revealed the above-mentioned antidepres-
sive self-medication, which was conse-
quently stopped. Tacrolimus trough levels 
returned to the previous range of 6–
10 mcg/L without change of dosage. Since 
tacrolimus is a substrate for CYP3A4 and 
P-gp (Zhou, 2008), the decrease in the 
blood trough concentrations of tacrolimus is 
likely to be due to the induction of 
CYP3A4 and P-gp by St. John’s wort. Low 
tacrolimus blood levels may present with 
the risk of under-immunosuppression and 
result in rejection episodes with the risk of 
graft loss. 
Another clinical relevance example is 
the interaction of St. John’s wort with the 
oral contraceptive pill. Several cases of 
women becoming pregnant unintentionly 
while taking oral contraceptives and St. 
John’s wort have been reported by authori-
ties in the UK (7 cases), Germany (4 cases) 
and Sweden (2 cases) (Murphy, 2002). An 
interesting case report described a 36-year-
old woman became pregnant unexpectedly 
while using a combined oral contraceptive, 
ethinylestradiol/dienogest (Schwarz et al., 
2003). An evaluation revealed that she be-
gan self-medicated with the over-the-
counter St. John’s wort extract Helari-
um®425 (Bionorica) with daily doses up to 
1700 mg approximately 3 months prior to 
conception. Prior to conception no other 
medication was taken except the hormonal 
contraceptive pills. The clearance of hor-
mones such as ethinylestradiol, nor-
ethindrone and ketodesogestrel has previ-
ously been shown to be increased by St. 
John’s wort (Hall et al., 2003; Murphy et 
al., 2005; Pfrunder et al., 2003). Even 
though, co-administration with a low hyper-
forin content St. John’s wort extract does 
not change the plasma concentrations of 
oral contraceptives (Will-Shahab et al., 
2009). Concomitant use of St. John’s Wort 
(at a daily consumption of 2.7 mg of hyper-
forin) was associated with a signiﬁcant in-
crease in the oral clearance of nore-
thindrone and a signiﬁcant reduction in the 
half-life of ethinylestradiol (Hall et al., 
2003). Serum concentrations of follicle-
stimulating hormone, luteinizing hormone, 
and progesterone were not changed by St. 
John’s wort. Breakthrough bleeding hap-
pened in 7 of 12 women consuming St. 
John’s wort compared with only 2 of 12 
women in the control group (Hall et al., 
2003). Changes in the plasma concentra-
tions of ethinylestradiol might also explain 
several reports of breakthrough bleeding 
(Hall et al., 2003; Murphy et al., 2005; 
Pfrunder et al., 2003). Induction of ethinyl-
estradiol and norethindrone metabolism 
caused by St. John’s wort is in agreement 
with increased CYP3A4 enzyme activity. 
The authors also suggested that women tak-
ing oral contraceptive pills should be ad-
vised to expect breakthrough bleeding and 
should consider adding a barrier method of 
contraception when using St. John’s wort.  
With regard to the herbal drug interac-
tions via CYP caused by St. John’s wort co-
administration, there were many case re-
ports in humans. Some of these are that are 
worth mentioning are as follows. Concomi-
tant administration, St. John’s wort causes a 
significant decrease in the blood concentra-
tions of cyclosporine A (Dresser et al., 
2003) as previously mentioned. It was sug-
gested that this was due to St. John’s wort 
inducing human CYP3A4 and also the drug 
transporter protein P-gp. This in turn in-
creased the elimination of cyclosporine A. 
Long term co-administration of St. John's 
wort with amitriptyline, reduced the plasma 
concentrations of amitriptyline (Venkata-
krishnan et al., 1999). Similarly the mecha-
nism was proposed to be attributed to the 
induction of CYP3A4. In addition, con-
sistent observations were found with other 
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CYP3A4-metabolized drugs. These includ-
ed the anti-HIV agents indinavir, nevirapine 
and ritonavir, in which co-administration of 
St. John's wort produced a considerably 
lower blood concentration of these anti-
HIV agents (Piscitelli et al., 2000). The 
suggested mechanism was attributed to the 
induction of CYP3A4 by St. John's wort.  
Furthermore, short-term (1-3 days) ad-
ministration of St. John’s wort did not in-
duce CYP3A4 or P-gp, and long term (14 
days) treatment is generally required to 
show the inductive effect (Markowitz et al., 
2000; Markowitz et al., 2003b). Wang et al. 
(2001) used midazolam as a specific 
CYP3A4 probe and found that long-term 
(300 mg, three times a day for 14 days) St. 
John's wort administration caused a signifi-
cant increase in oral clearance of midazo-
lam. While short-term administration of St. 
John's wort (900 mg single dose) did not 
have significant effect on CYP activities. 
This significant increase in oral clearance 
of midazolam was due to the induction of 
CYP3A4 mediated by St. John's wort co-
administration (Wang et al., 2001). The au-
thors commented that reduction in thera-
peutic efficacy of drugs metabolized by 
CYP3A4 should be anticipated during long-
term administration of St. John's wort. The 
induction of CYP3A4 initiated by St. John's 
wort was demonstrated to be time-
dependent. This was illustrated by evidence 
showing that oral clearance of midazolam 
was significantly increased after admin-
istration of St. John's wort (300 mg three 
times daily for 14 days), and CYP3A4-
induced activity progressively returned to 
basal levels approximately 1 week after 
completion of St. John's wort treatment 
(Imai et al., 2008). 
In addition, a case report of drug inter-
action between St. John's wort and metha-
done was documented (Eich-Höchli et al., 
2003). In this particular report it was found 
that prescription of St. John's wort de-
creased methadone blood levels and in-
duced withdrawal symptoms which, if not 
correctly identified and handled, might 
cause unnecessary discomfort to the patient, 
leading to resumption of illicit drug use. 
Methadone is mainly metabolized by hu-
man CYP3A4 enzyme. Thus, co-admini-
stration with St. John's wort, as expected, 
caused induction of CYP3A4 and increased 
the metabolism and clearance of metha-
done. Another CYP3A4-metabolized drug 
that was reported to significantly affected 
by St. John's wort administration, was 
simvastatin. Taken with St. John's wort 
concomitantly, St. John’s wort caused a 
marked decrease in the blood concentra-
tions of simvastatin (Sugimoto et al., 2001). 
The induction of CYP3A and P-gp by St. 
John's wort was attributed to an increase in 
the elimination of simvastatin, and this 
caused a decrease in the blood concentra-
tions of this drug during St. John's wort co-
administration. Besides causing induction 
of CYP3A4, St. John's wort may also in-
duce two other human CYP enzymes, 
CYP1A2 and CYP2C9. A case report de-
scribed a 42-year old female started self-
medicating with the over-the-counter St. 
John’s wort extract supplement. This 
caused a significant decrease in the plasma 
concentrations of theophylline possibly due 
to the induction of CYP1A2, the major en-
zyme responsible for the metabolism of 
theophylline (Nebel et al., 1999). However, 
this observation was not confirmed by a 
well defined pharmacokinetic study con-
ducted by Morimoto et al. (2004). They 
found that a 15-day treatment with St. 
John's wort did not cause any significant 
change in the pharmacokinetics of theo-
phylline (Morimoto et al., 2004). Thus, in-
dicating that the effect of St. John’s wort on 
the activity of human CYP1A2 needs fur-
ther investigation. 
Evidence suggesting a possible induc-
tion of CYP2C9 was derived from a clinical 
study carried out by Jiang et al. (2004). 
Their results have shown that St. John's 
wort significantly induced the clearance of 
both S-warfarin and R-warfarin, which in 
turn caused a significant reduction in the 
pharmacological effect of racemic warfarin. 
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On the other hand, St. John’s wort does not 
have a significant influence on the pharma-
cokinetics of drugs such as ibuprofen (Bell 
et al., 2007) and carbamazepine (Burstein et 
al., 2000). Even though CYP2C9 is primari-
ly responsible for the clearance of ibu-
profen and carbamazepine. 
A case report described a psychiatric 
patient who experienced adverse reactions 
from clozapine and St. John’s wort interac-
tion (van Strater and Bogers, 2012). This 
patient was stable on a fixed dose with sta-
ble plasma level of clozapine. Her psychiat-
ric condition deteriorated after she started 
self-medicating with St. John’s wort. This 
was consistent with a decreased plasma 
clozapine concentration during the St. 
John’s wort’s co-administration. After the 
withdrawal of St. John’s wort, the reduced 
plasma clozapine level and the psychiatric 
condition normalized. It is likely that St. 
John’s wort induced CYP3A4, leading to a 
decrease in plasma clozapine levels in this 
patient. However, some studies have shown 
that plasma clozapine levels would decrease 
in interaction with St. John’s wort as a re-
sult of induction of CYP1A2 enzyme (Ne-
bel et al., 1999; Miller, 2001). Physicians 
should be alert to patients self-medicating 
with over-the-counter medicines, especially 
St. John’s wort which can lower clozapine 
concentrations below the therapeutic range 
(van Strater and Bogers, 2012). 
In summary, a great number of studies 
have shown that St. John's wort can pro-
duce both pharmacokinetic and pharmaco-
dynamic interactions. The clinical conse-
quences of such St. John's wort-drug inter-
actions are dependent upon a range of fac-
tors such as the dosage, duration and thera-
peutic range of the treatment. Hyperforin 
appears to play an important role in the in-
duction effect on CYP and P-gp caused by 
St. John's wort. As the potential for St. 
John’s wort-drug interactions is very signi-
ficant therefore, patients taking prescription 
drugs should be strongly advised not to take 
herbal products containing St. John's wort. 
Well-documented and clinically relevant 
interactions between St. John's wort and 
drugs include: (1) reduced blood cyclospor-
ine A concentration associated in some cas-
es to rejection episodes; (2) reduced effica-
cy of the oral contraceptive pill, resulting in 
unwanted pregnancy, and (3) reduced 
plasma concentration of antiretroviral, e.g. 
indinavir, nevirapine, and anticancer drugs, 
e.g. imatinib, irinotecan (Izzo, 2012). Fur-
thermore the use of St. John's wort prepara-
tions is not recommended in patients taking 
immunosuppressants or cardiovascular 
drugs. When St. John’s wort needs to be 
taken with other medications, it is recom-
mended that practitioners should only use 
St. John's wort preparations with a low hy-
perforin content and ensure a careful moni-
toring scheme. It is also suggested that be-
cause of the reduction in the bioavailability 
of oral contraceptives administered concur-
rently with St. John's wort, women taking 
St. John's wort preparations should utilize 
additional preventive methods to avoid un-
intended pregnancy. When compared with 
earlier studies that employed young sub-
jects, the data suggest that some age-related 
changes in CYP responsivity to herbal sup-
plementation may be present (Gurley et al., 
2005a). Therefore, concomitant ingestion of 
herbal supplements with prescription medi-
cations should be strongly discouraged in 
the elderly. 
 
Garlic 
Garlic (Allium sativum; family Amaryl-
lidaceae) is the third best-selling herbal 
supplement in the United States. This is 
mainly due to the number of its clinically 
established pharmacological properties – 
antihypertensive, hypolipidemic, antiathe-
rogenic, antitumorigenic, fibrinolytic, anti-
carcinogenic, immunomodulatory, antimi-
crobial and hypoglycemic activities (Foster 
et al., 2007). Garlic is widely used around 
the world for its pungent flavor as a season-
ing or condiment. It is also taken in the 
form of an extract in dietary supplements. 
Fresh garlic and garlic in dietary supple-
ment form may have different physiological 
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effects and properties, with both forms pur-
ported to have antibacterial and cholesterol-
lowering properties. Daily dosages general-
ly recommended in the literature for adults 
are 4 g (1-2 cloves) of raw garlic, one 300 
mg dried garlic powder tablet (standardized 
to 1.3 % allicin or 0.6 % allicin yield) two 
to three times per day, or 7.2 g of aged gar-
lic extract per day (Tattelman, 2005). Oil-
soluble compounds also present in garlic, 
mainly allicin, sulﬁdes, ajoenes, and vinyl-
dithiins, are quickly metabolized in the 
body after consumption and are not found 
in the urine and blood. 
Organosulfur compounds, flavonoids, 
sapogenins and saponins, selenium com-
pounds and fructosamines have been recog-
nized as the main bioactive principles in 
raw garlic and different garlic supplements 
(Berginc and Kristl, 2012). Polyphenolic 
compounds (i.e., flavonoids) apigenin, 
quercetin, nobiletin, tangeretin, rutin, allix-
in, myricetin and bergamottin from garlic 
are good antioxidants with potential cardio-
preventive and anticancer activities (Berg-
inc and Kristl, 2012). Flavonoids have also 
been shown to modulate the activities of 
intestinal/hepatic transporters (P-glycopro-
tein – P-gp, multidrug resistance-associated 
protein 2 - MRP-2, breast cancer resistance 
protein - BCRP, organic anion-transporting 
polypeptide - OATP) and enzymes (mainly 
CYP) in vitro. Therefore, these increase the 
probability of garlic-drug interactions. 
Pharmaceutical products developed 
from garlic bulbs/cloves are made available 
in the forms of powders, oily preparations, 
or aqueous-alcoholic extracts of fresh or 
aged garlic. Due to the complex chemistry, 
different manufacturing processes result in 
preparations of quite different chemical 
composition and pharmaceutical properties. 
This in turn may yield the products with 
different pharmacological, safety, and bio-
availability characteristics (Greenblatt et 
al., 2006b; Johne and Roots, 2005). 
Up to now, the identified active constit-
uents of garlic include alliin, allinase, dial-
lyldisulfide, ajoens, and others. Alliin is 
enzymatically converted to allicin, the ma-
jor garlic component, which displays con-
siderable chemical instability and is quickly 
degraded to an array of organosulfur com-
pounds (e.g., diallyl sulfide, diallyl disul-
fide, diallyl trisulfide) that are supposed to 
ultimately present the main pharmacologi-
cal effects (Lam and Ernst, 2006). 
Even though the use of garlic prepara-
tions is extremely popular, preclinical evi-
dence and clinical case reports on the po-
tential garlic drug interactions have been 
documented. There were also some sus-
pected pharmacodynamic-based drug inter-
actions associated with garlic use. Well-
designed clinical studies assessing drug in-
teractions with garlic preparations are re-
markably very limited (Hermann and von 
Ritcher, 2012). Fukao et al. (2004) investi-
gated the in vivo effect of garlic allyl sul-
fides on the phase I and phase II drug-
metabolizing enzymes in rats. A highly pu-
rified form of each sulfide was adminis-
tered i.p. as a bolus to rats at a concentra-
tion of 10 or 100 micromol/kg body weight 
for 14 consecutive days. As to the phase I 
enzymes, diallyl sulfide (100 micromol/kg) 
slightly but significantly increased CYP2E1 
activity (1.6-fold vs. control), whereas dial-
lyl disulfide and diallyl trisulfide did not 
affect it or the hepatic total CYP level or 
CYP1A1/2 activity. With regard to the 
phase II enzymes, diallyl trisulfide (10 mi-
cromol/kg) and diallyl disulfide at a 10-fold 
higher dose (100 micromol/kg) significant-
ly increased the activities of glutathione S-
transferase, quinone reductase, and antioxi-
dative enzyme glutathione peroxidase; 
whereas diallyl sulfide did not. The authors 
suggested that the upregulation of glutathi-
one S-transferase enzyme by garlic sulfide 
constituents may have been implicated in 
the detoxification of carcinogens (Fukao et 
al., 2004). On the other hand, conflicting 
results have been reported in which garlic 
was shown to inhibit the activities of 
CYP2E1, CYP2C9, and CYP2C19 (An and 
Morris, 2010). 
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Two in vitro studies on cell-free en-
zymes demonstrated that garlic constituents 
competitively inhibit several recombinant 
CYP enzymes, namely CYP2C9, CYP2C19 
and CYP3A4 (Foster et al., 2001; Zou et 
al., 2002). Aqueous extracts from odorless 
garlic products inhibited CYP3A4 to a 
slightly greater extent than CYP2C9. 
Steam-distilled garlic oil inhibited CYP2C9 
and CYP3A4 to a comparable extent, while 
freeze-dried garlic tablets did not inhibit 
CYP2C9 activity (Zou et al., 2002). Allicin, 
a major organosulfur constituent of some 
garlic supplements, was a more potent in-
hibitor of cDNA-expressed CYP2C9 than 
CYP3A4 (Zou et al., 2002). On the other 
hand, a study using human liver micro-
somes found that only two garlic constitu-
ents, S-allyl- or S-methyl-L-cysteine at 
0.1 mg/mL significantly inhibited CYP3A4, 
with no appreciable effect on CYP2C9, 
CYP2C19 or CYP1A2 (Foster et al., 2001). 
Another in vitro study investigated the ef-
fects of garlic phytochemicals and aged 
garlic extract on the hepatic pharmacokinet-
ics of two antiretroviral drugs (saquinavir 
and darunavir) which are primarily metabo-
lized by human CYP3A4 (Berginc et al., 
2010). The results have shown that the gar-
lic phytochemicals including diallyl sulfide 
and S-methyl-L-cysteine, and aged garlic 
extract inhibited CYP3A4-mediated metab-
olism of both anti-retroviral drugs, saqui-
navir and darunavir. 
In addition, Ho and co-workers (Ho et 
al., 2010) used an immortalized human 
hepatocyte, Fa2N-4 cell line, to evaluate the 
effects of garlic extract on the activity of 
CYP2C9 and CYP3A4 in the cells. They 
found that garlic extract suppresses 
CYP2C9 activity without affecting 
CYP3A4. These results suggest that the 
concomitant administration of garlic sup-
plements with drugs metabolized by 
CYP2C9 may lower metabolic clearance of 
the CYP2C9 drugs and potentially cause 
adverse drug reactions. 
A number of clinical studies were con-
ducted to determine the effects of garlic 
supplements or garlic dietary constituents 
on the activities of human CYP enzymes. 
The effects of acute administration of die-
tary supplement garlic oil extract, diallyl 
sulphide on cytochrome CYP2E1 activity in 
healthy volunteers were evaluated using the 
selective CYP2E1 probe substrate, chlor-
zoxazone (Loizou and Cocker, 2001). 
These studies have demonstrated that garlic 
dietary constituent diallyl sulfide, adminis-
tered at dietary concentration can inhibit 
human CYP2E1 activity. The inhibitory 
effect of diallyl sulfide may be additive 
with daily consumption of allium vegeta-
bles in particular. This may explain the 
lower CYP2E1 phenotypic metabolic ratios 
measured in various European and Mexican 
cohorts and is consistent with the lower in-
cidence of stomach, liver and colon cancers 
observed in southern Europeans (Loizou 
and Cocker, 2001). These results are con-
sistent with an earlier study on effects of 
garlic oil extract on CYP2E1 activity, 
which also employed chlorzoxazone as a 
selective CYP2E1 probe (Gurley et al., 
2002, 2005b). Repeat administration of gar-
lic oil over 28 days was shown to moderate-
ly reduce CYP2E1 activity by 39 % in 
healthy adult subjects (Gurley et al., 2002) 
and by approximately 22 % in elderly indi-
viduals (Gurley et al., 2005a). Of note, 
these data derived from human study are in 
contrast with those results obtained by Fu-
kao et al. (2004) in which they investigated 
the in vivo effect of garlic allyl sulfides on 
the CYP2E1 enzyme in rats. Fukao et al. 
(2004) reported that diallyl sulfide (100 mi-
cromol/kg) significantly increased CYP2E1 
activity (1.6-fold vs. control) in rats sug-
gesting garlic diallyl sulfide induced rat 
CYP2E activity. This difference in their 
results could simply be due to species dif-
ference in CYP activity and specificity.  
The benzodiazepines alprazolam and 
midazolam, as well as the anticancer drug 
docetaxel are extensively used as probes for 
CYP3A4 activity because they are exclu-
sively metabolized by intestinal and hepatic 
CYP3A4. Markowitz and co-workers ex-
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amined the influence of a garlic extract on 
the activity of CYP2D6 and CYP3A4 in 14 
healthy volunteers (Markowitz et al., 
2003c). Probe substrates dextromethorphan 
(CYP2D6) and alprazolam (CYP3A4) were 
administered orally at baseline and again 
after treatment with garlic extract (3 x 
600 mg twice daily) for 14 days. They 
found no significant differences in the ac-
tivity of CYP2D6 between the baseline and 
garlic phases. For CYP3A4 as assessed by 
using alprazolam, there were no significant 
differences in pharmacokinetic parameters 
of alprazolam at baseline and after garlic 
extract treatment. These results indicate that 
garlic extracts are unlikely to alter the dis-
position of co-administered medications 
primarily metabolized by CYP2D6 or 
CYP3A4. Latter study also showed that a 
28-day treatment with garlic oil did not 
have a significant effect on the pharmaco-
kinetics of midazolam in the elderly 
(Gurley et al., 2005a). Moreover, Cox et al. 
(2006) have demonstrated that a 12-day 
treatment with garlic did not affect the 
pharmacokinetics of a CYP3A4 substrate, 
docetaxil in 10 women with metastatic 
breast cancer. The lack of garlic treatment 
on the activity of human CYP3A4 in 
healthy subjects was further confirmed by a 
clinical study using another CYP3A4 sub-
strate drug, saquinavir. In this study, the 
results have shown that garlic extract had 
no significant effect on saquinavir pharma-
cokinetics and hepatic CYP3A4 function 
measured by the erythromycin breath test 
(Jacek et al., 2004). Collectively, these tri-
als signify that garlic has no effect on the 
CYP3A4 enzyme in humans. These find-
ings are consistent with an in vitro observa-
tion in which a number of water-soluble 
garlic components of aged garlic have been 
shown to not affect the activity of human 
CYPs in vitro (Greenblatt et al., 2006b). 
These suggest that drug interactions involv-
ing inhibition of CYP3A4 enzyme by aged 
garlic extract are very unlikely. 
Conflicting results were reported in a 
clinical study showing a garlic supplement 
containing alliin and allicin signiﬁcantly 
decreased the AUC and Cmax of the prote-
ase inhibitor saquinavir (Piscitelli et al., 
2002a). It suggested that garlic supplement 
caused an induction of human CYP3A4. 
This was not consistent with the findings 
described previously (Jacek et al., 2004; 
Markowitz et al., 2003c). The induction ef-
fect of garlic supplement could be a result 
of the use of higher doses, at least with re-
spect to allicin content, or possibly the 
longer dosing period (20 days versus 14 
days in Markowitz et al.’s study). Another 
study with supplements devoid of allicin, 
for a period of 4 days, also indicated chang-
es in pharmacokinetic parameters of ri-
tonavir, although the results were not statis-
tically signiﬁcant (Gallicano et al., 2003). 
The authors also commented that as the ef-
fects of both ritonavir and garlic on enzyme 
inhibition and enzyme induction are com-
plicated, the results of their study should 
not be extrapolated to steady state condi-
tions, where the possibility of an interaction 
still needs to be evaluated (Gallicano et al., 
2003). Both saquinavir and ritonavir not 
only are metabolized by CYP3A4 but also 
are substrates for P-glycoprotein (Lee et al., 
1998). It was proposed that the pharmaco-
kinetic changes observed for saquinavir and 
ritonavir after garlic treatment may not be 
due to induction of CYP3A4 but rather the 
inﬂuence of garlic constituents on another 
enzyme or transporter such as P-
glycoprotein (Markowitz et al., 2003c). 
However, any conclusions on the metabolic 
effects of garlic based on inter-study com-
parisons are somewhat restricted. This is 
mainly because all published interaction 
studies have used different garlic formula-
tions, treatment durations, and probe sub-
strates (Markowitz et al., 2003c).  
The well-known adverse interaction be-
tween garlic and warfarin is probably due to 
the antiplatelet effects of garlic. A number 
of case reports have proposed that garlic 
may influence platelet function and blood 
coagulation which can lead to a risk of 
bleeding (Borrelli et al., 2007). Two pa-
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tients having the international normalized 
ratio (INR) previously stabilized on warfa-
rin were found to have changed INR values 
after garlic intake (Sunter, 1991). There is 
also evidence that some of the antiplatelet 
activity might be irreversible and thus it has 
been suggested that patients stop ingestion 
at least seven days prior to surgery (Ang-
Lee et al., 2001). Few case reports have 
highlighted the possibility that garlic may 
increase the risk of bleeding, particularly in 
patients undergoing surgery. In contrast, the 
results obtained from two clinical studies 
have suggested that garlic (enteric-coated 
tablets or aged garlic extract) did not alter 
the pharmacokinetics or pharmacodynamics 
of warfarin and that garlic had no serious 
haemorrhagic risk for adequately monitored 
patients receiving warfarin (Macan et al., 
2006; Mohammed Abdul et al., 2008). 
Astonishingly, garlic has been suggested to 
decrease the INR of the anticoagulant flu-
indione in an 82-year-old man (Pathak et 
al., 2003). A rational explanation is not 
known for such an interaction. 
The above evidence indicates reliably 
that neither single nor repeat dose admin-
istrations of several garlic formulations up 
to 28 days might have the ability to exert 
important alterations (i.e., inhibition or in-
duction) of the activities of CYP1A2, 
CYP2D6, or CYP3A4 in humans. These 
CYP isozymes play an important role in the 
metabolic pathways of many drugs that are 
likely to be co-administered with garlic 
supplements. In clinical expressions, these 
findings reveal that garlic preparations are 
unlikely to modify the disposition of co-
administered drugs which are metabolized 
by these CYP enzymes. In contrast, repeat 
administration of garlic oil over 28 days 
appeared to moderately decrease CYP2E1 
activity in healthy and elderly individuals 
(Gurley et al., 2002, 2005a). However, as 
the overall extent of CYP2E1 inhibition by 
garlic is moderate, and scarcely any clini-
cally used drugs are dependant on CYP2E1 
as an exclusive or predominant metabolic 
pathway (except chlorzoxazone), the de-
tected effects of garlic on CYP2E1 do not 
emerge to have crucial clinical implications 
(Hermann and von Ritcher, 2012; Yuan et 
al., 2004). This viewpoint is further sup-
ported by a study in healthy adult subjects, 
in which a 3-month administration of aged 
garlic extract (10 mL once daily) did not 
have any significant effect on oxidative me-
tabolism of acetaminophen, to which 
CYP2E1 is known to be an important con-
tributor, besides CYP3A4 and CYP1A2 
(Gwilt et al., 1994).  
Collectively, there is sound consistent 
evidence that recommended doses of many 
varieties of garlic preparations do not have 
any significant effect on CYP3A4 activity 
in vivo. To our knowledge, the question of 
whether garlic preparations might be en-
gaged in transporter-based drug interactions 
has not yet been dealt with in human phar-
macokinetic studies. Additionally the pre-
clinical evidence regarding this question is 
still not well recognized (An and Morris, 
2010). With the limited existing evidence 
from human in vivo drug interaction stud-
ies, there is no indication that garlic may 
present any remarkable or clinically im-
portant metabolism-based pharmacokinetic 
interactions with drugs, mainly cleared by 
CYP1A2, CYP2D6, CYP2E1, or CYP3A4 
enzymes. Therefore, many of the findings 
from in vitro studies still need to be con-
firmed by results from clinical interaction 
studies before we can implement recom-
mendations for herbal drug interactions. 
 
Goldenseal 
Goldenseal (Hydrastis canadensis, or-
angeroot) is a perennial herb in the butter-
cup family Ranunculaceae, indigenous to 
southeastern Canada and the northeastern 
United States. Botanical goldenseal sup-
plement is used for the common cold and 
upper respiratory tract infections, as well as 
stuffy noses and hay fever. Some people 
use goldenseal for digestive disorders in-
cluding stomach pain and swelling (gastri-
tis), peptic ulcers, colitis, diarrhea, consti-
pation, and hemorrhoids, as well as men-
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strual disorders. In addition, goldenseal is 
being used as a topical antimicrobial reme-
dy to disinfect cuts and scrapes (Weber et 
al., 2003). Goldenseal contains a number of 
isoquinoline alkaloids such as hydrastine, 
berberine, berberastine, hydrastinine, tetra-
hydroberberastine, canadine, and cana-
lidine. Hydrastine and berberine are the 
main active constituents (Weber et al., 
2003). Commercial dietary supplement 
preparations of goldenseal standardized ex-
tracts are available in liquid, tablet, and 
capsule forms. Recommended doses of the 
powdered root vary widely and range from 
750 mg to 6 grams in tablet or capsule form 
per day, to be given 2 to 3 times daily. 
Goldenseal preparations possess wide-
spread popularity and are among the top 20 
bestselling botanical products in the United 
States (Ettefagh et al., 2011). 
Evidence obtained from in vitro studies 
have suggested that goldenseal root was the 
most potent inhibitor of CYP3A4 among 21 
popular herbal products tested for the inhi-
bitory potential. A number of clinical stud-
ies on goldenseal and drug interactions 
have been reported. Sandhu et al. (2003) 
investigated the influence of goldenseal 
root on the pharmacokinetics of the 
CYP3A4 substrate indinavir in 10 healthy 
volunteers. The pharmacokinetics of a sin-
gle oral dose (800 mg) indinavir were char-
acterized in subjects before and after 14 
days of treatment with goldenseal root 
(1140 mg twice daily). No statistically sig-
nificant differences in peak concentration 
(11.6 vs. 11.9 mg/L) or oral clearance (26.8 
vs. 23.9 mg*h/L) of indinavir were detected 
following treatment with goldenseal root. 
These results suggest that patients being 
treated with indinavir can safely take gold-
enseal root and that interactions with other 
drugs metabolized by hepatic CYP3A4 are 
unlikely (Sandhu et al., 2003). 
Single-time point phenotypic metabolic 
ratios were used to determine if long-term 
supplementation of goldenseal (Hydrastis 
canadensis) affected CYP1A2, CYP2D6, 
CYP2E1, or CYP3A4 activity (Gurley et 
al., 2005b) in 12 healthy volunteers. They 
were given a pretreatment of goldenseal 
dietary supplement for 28 days. Probe drug 
cocktails of midazolam (CYP3A4) and caf-
feine (CYP1A2), followed 24 hours later by 
chlorzoxazone (CYP2E1) and debrisoquine 
(CYP2D6), were administered before (base-
line) and at the end of supplementation. 
Presupplementation and postsupplementa-
tion phenotypic trait measurements were 
determined for activity of CYPs of interest 
as previously described (Gurley et al., 
2005b). Comparisons of pre-supplementa-
tion and post-supplementation phenotypic 
ratio means revealed significant inhibition 
(approximately 40 %) of CYP2D6 and 
CYP3A4 activity for goldenseal. Whereas, 
there was no considerable effect of golden-
seal on CYP1A2 and CYP2E1 activities. 
Thus, this was the first clinical study con-
vincingly indicating that goldenseal root 
extract, given at recommended doses, 
showed to remarkably inhibit CYP2D6 and 
CYP3A4 in vivo. Accordingly, serious ad-
verse interactions may rise from the con-
comitant intake of goldenseal supplements 
and drugs that are metabolized by CYP2D6 
and CYP3A4 (Gurley et al., 2005b). 
Researchers from the same group have 
continued studying the effects of goldenseal 
supplementation on human CYP3A4 activi-
ty (Gurley et al., 2008a). This was evaluat-
ed by using midazolam as a phenotypic 
probe for human CYP3A4 and studied in 16 
healthy volunteers. The subjects were ran-
domly assigned to receive either goldenseal 
or placebo for 14 days. Midazolam (8 mg) 
was administered before and after golden-
seal supplementation, and pharmacokinetic 
parameters were assessed. The results have 
shown that means of midazolam’s AUC0-∞ 
and Cmax were increased by approximately 
63 % and 40 %, respectively, upon golden-
seal supplementation. These indicated that 
goldenseal supplementation caused signifi-
cant inhibition of CYP3A4 (Gurley et al., 
2008a). In contrast, the potent CYP3A4 in-
hibitor clarithromycin produced about 5.5-
fold (i.e., 548 %) and about 2-fold (217 %) 
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increases in midazolam’s AUC0-∞ and 
Cmax values, respectively (Gurley et al., 
2008a). Therefore, according to current 
FDA drug interaction guideline recommen-
dations (US Department of Health and Hu-
man Services, Food and Drug Administra-
tion Center for Drug Evaluation and Re-
search 2012), these data classified golden-
seal root extract, at the given recommended 
dose, as a weak inhibitor of CYP3A4 (i.e., 
< 2-fold increase in AUC of the sensitive 
CYP3A4 probe midazolam). 
Gurley et al. (2008b) also conducted a 
similar study to determine the effects of 
goldenseal supplementation on in vivo ac-
tivity of another human CYP enzyme, 
CYP2D6. Healthy subjects (N = 16) were 
randomized to receive a standardized gold-
enseal extract for 14 days on separate occa-
sions. The CYP2D6 probe substrate, de-
brisoquine (5 mg), was administered before 
and at the end of supplementation. Pre- and 
post-supplementation phenotypic trait 
measurements were assessed for CYP2D6 
activity (Gurley et al., 2008b). Comparisons 
of pre- and post-supplementation, results 
revealed significant inhibition (approxi-
mately 50 %) of CYP2D6 activity caused 
by goldenseal supplementation. Conse-
quently, adverse herbal drug interactions 
may result with concomitant ingestion of 
goldenseal supplements and drugs that are 
CYP2D6 substrates (Gurley et al., 2008b). 
In addition, there were other two clini-
cal studies evaluating the effect of berber-
ine, a major alkaloid constituent in golden-
seal extract, on the pharmacokinetics of cy-
closporine A. An immonosupressive agent, 
cyclosporine A is a drug with narrow thera-
peutic index and primarily metabolized by 
CYP3A4. These studies were conducted in 
Chinese renal transplant patients (Wu et al., 
2005) and in healthy Chinese subjects (Xin 
et al., 2006). The first study was a random-
ized, controlled clinical trial in 104 renal 
transplant recipients, in which Wu and col-
leagues (Wu et al., 2005) examined the ef-
fects of oral berberine supplementation 
(tablets 200 mg, three times a day, for 3 
months) on the pharmacokinetics of cyclo-
sporine A. Blood trough concentration of 
cyclosporine A and biochemistry indexes 
for hepatic and renal functions were deter-
mined. For the comprehensive pharmacoki-
netic study, 6 renal-transplant recipients 
were treated with a 3-mg/kg dose of cyclo-
sporine A, twice a day, before and after oral 
co-administration of 200 mg berberine three 
times a day, for 12 days. The trough blood 
concentrations and the ratios of concentra-
tion/dose of cyclosporine A in the berber-
ine-treated group increased by 88.9 % and 
98.4 %, respectively, compared with those 
at baseline (P < 0.05). For the berberine-
free group, these parameters rose by 64.5 % 
and 69.4 %, respectively, when compared 
to those at baseline (P < 0.01). However, 
the final blood concentrations and the ratios 
of concentration/dose of cyclosporine A in 
berberine-treated patients were still 29.3 % 
and 27.8 %, respectively, higher than those 
in berberine-free patients (P < 0.05). No 
significant effects on liver or renal func-
tions were detected under co-administration 
of berberine. For the comprehensive phar-
macokinetic study, the results showed that 
following co-administration of berberine in 
six patients for 12 days, the mean AUC of 
cyclosporine A was increased by 34.5 % (P 
< 0.05). The average percentage increase in 
the steady-state drug concentration (Css) 
was 34.5 % (P < 0.05). The mean half-life 
(t1/2) of cyclosporine A was increased by 
2.7 h (P < 0.05). In addition, the average 
percentage decrease in apparent oral clear-
ance (CL/F) of cyclosporine A was 40.4 % 
(P < 0.05). This study has demonstrated that 
berberine can markedly elevate the blood 
concentration of cyclosporine A in renal-
transplant recipients in both clinical and 
pharmacokinetic trials. This combination 
may allow a reduction of the cyclosporine 
A dosage. The mechanism for this interac-
tion is most likely explained by inhibition 
of CYP3A4 by berberine in the liver and/or 
small intestine (Wu et al., 2005). 
The second study on effects of berber-
ine on the pharmacokinetics of cyclosporine 
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A was carried out in 12 healthy Chinese 
volunteers (Xin et al., 2006). Six volunteers 
were orally treated with 0.3 g berberine, 
twice daily for 10 days. Pharmacokinetic 
studies of cyclosporine A at 6 mg/kg dos-
age were performed before and at the end 
of the berberine treatment period. Another 
six healthy volunteers participated in the 
pharmacokinetic study with 3 mg/kg cyclo-
sporine A, in which the second single dose 
of 3 mg/kg cyclosporine A was given con-
comitantly with a single oral dose of 0.3 g 
berberine. The blood cyclosporine A con-
centrations were monitored. In the pharma-
cokinetic study with 6 mg/kg cyclosporine 
A and time-separated intake of the last ber-
berine dose, berberine did not cause any 
significant changes in the pharmacokinetic 
parameters of cyclosporine A. However, in 
the trial with 3 mg/kg cyclosporine A and 
the concomitant administration of cyclo-
sporine A and berberine, the average per-
centage increase in AUC of cyclosporine A 
was 19.2 % (P < 0.05), without altering 
elimination half-life, and apparent oral 
clearance (CL/F). The present results sug-
gest that berberine can increase the oral bio-
availability of cyclosporine A at the dosage 
of 3 mg/kg (Xin et al., 2006). The berber-
ine-mediated increase in cyclosporine A 
bioavailability may be partly attributed to a 
decrease in liver and/or intestinal metabo-
lism through the inhibition of CYP3A4 in 
the liver and/or gut wall. 
The outcomes derived from these two 
clinical studies even though are not totally 
consistently, but the evidence pointed to a 
moderest inhibition of human CYP3A4 iso-
zyme by berberine. However, with even 
small changes in pharmacokinetic parame-
ters including AUC, Css and apparent oral 
clearance, caused by co-administration with 
berberine, it may be important to consider 
in case of concomitant treatment with nar-
row therapeutic index drugs that are sub-
strates of CYP3A4, such as cyclosporine A. 
With regard to the effects of goldenseal 
root extract constituent, berberine on other 
human CYP enzymes, a recent study has 
described findings on these enzymes. This 
particular study was conducted in 18 Chi-
nese healthy subjects who received orally 
either placebo or berberine capsules at a 
dose of 300 mg three times a day (= 900 
mg/day) for 14 days (Guo et al., 2012). 
Phenotypic effects of berberine supplemen-
tation on the activities of various CYP iso-
zymes were evaluated by the administration 
of the CYP-specific probe substances 
namely caffeine (CYP1A2), losartan 
(CYP2C9), omeprazole (CYP2C19), dex-
tromethorphan (CYP2D6), and midazolam 
(CYP3A4). A remarkable decrease in 
CYP2D6 activity was observed followed 
berberine supplementation, as the CYP2D6 
index, 0-8 h urinary dextromethorphan/ 
dextrorphan ratio increased about 9-fold 
(P < 0.01). In addition, the losartan/E-3174 
ratio doubled (P < 0.01) after berberine ad-
ministration, indicating a notable decrease 
in CYP2C9 activity. In contrast, CYP3A4 
activity was only modestly inhibited, as the 
Cmax, AUC0-∞, and AUC0-12h of mid-
azolam were significantly increased after 
berberine treatment. Accordingly, the oral 
midazolam clearance was also modestly 
decreased by 27 % (P < 0.05). There were 
no significant changes of the other probe 
substances caffeine (CYP1A2) and ome-
prazole (CYP2C19). These results suggest-
ed that repeated administration of berberine 
(900 mg/day) markedly decreased the activ-
ity of CYP2D6, and appears to modestly 
inhibit CYP2C9 and CYP3A4 activities. On 
the other hand, berberine administration 
does not change CYP1A2 and CYP2C19 
function. Herbal drug interactions should be 
considered when berberine is concomitantly 
administered with drugs that are metabo-
lized by CYP2D6, CYP2C9 and CYP3A4 
(Guo et al., 2012). 
In summary, a number of pharmacoki-
netic interaction studies with different gold-
enseal root extract products at daily doses 
up to 4 g revealed overall consistent results 
and categorized goldenseal root extract as a 
weak inhibitor of CYP3A4 and CYP2D6 
enzymes, according to FDA drug interac-
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tion guideline criteria. Of note, the existing 
evidence for this assessment is most vigor-
ous for CYP3A4, and based on phenotypic 
serum ratios or metabolite urinary recovery 
data only, for CYP2D6 enzyme. Moreover, 
results from single studies suggest that 
goldenseal root extract does not alter the 
activities of CYP1A2 and CYP2E1 en-
zymes. To our knowledge, there is no in-
formation available in respect to potential 
in vivo effects of goldenseal on CYP2C9 
and CYP2C19 enzymes. In addition, the 
effects of goldenseal root extract constitu-
ent, berberine were similar to those of gold-
enseal root extract. The evidence suggests 
that berberine products have weak potential 
to inhibit CYP3A4 and CYP2D6, but is un-
likely to alter CYP1A2 and CYP2C19 en-
zymes. However, these findings and their 
clinical implication have to be confirmed 
by future studies. To be safe, care should be 
applied when goldenseal root extract or 
berberine products are co-administered with 
narrow therapeutic index drugs, which its 
major metabolic pathway is catalyzed by 
CYP3A4, CYP2D6 or CYP2C9 enzymes. 
 
Milk thistle 
Milk thistle (Silybum marianum) is a 
thistle of the genus Silybum, a flowering 
plant of the daisy family (Asteraceae). The 
plant is native to the Mediterranean regions 
of Europe, North Africa and the Middle 
East. The name "milk thistle" originates 
from a feature of the leaves, which are no-
tably banded with splashes of white. Histo-
rically, these milky bands were said to be 
Mother Mary's milk, and this is the origin 
of another common name, St. Mary's this-
tle. For many centuries extracts of milk 
thistle have been recognized as “liver ton-
ics”. Milk thistle has been reported to have 
protective effects on the liver and to greatly 
improve its function. It is typically used to 
treat liver cirrhosis, chronic hepatitis, toxin-
induced liver damage including the preven-
tion of severe liver damage from Amanita 
phalloides ('death cap' mushroom poison-
ing), and gallbladder disorders (Pradhan 
and Girish, 2006). Milkthistle, along with 
dandelion and other extracts are often re-
ferred to as hangover cures as the bitter 
tincture helps organs clear toxins after 
heavy drinking. 
Milk thistle is one of the oldest and 
most extensively studied plants in the 
treatment of alcoholic, toxic, and viral liver 
diseases. Many years of research disclose 
the active flavanoid-lignan (flavanolignan) 
group of constituents, called silymarin has 
liver-protective and regenerative properties, 
as well as antioxidant effects. Silymarin 
represents a mixture of the flavonolignan 
constituents’ sylibin (silibinin), isosilybin, 
silidianin, and silichristin. Silymarin is ex-
tracted from dried milk thistle seeds, in 
which it is contained at higher contents than 
in other parts of the plant. Silymarin has 
structural similarities to steroid hormones, 
which may be linked to its pharmacological 
actions. Silybin is the predominant and 
pharmacologically most active component, 
constituting approximately 60-70 % of the 
isomers, followed by silychristin (20 %), 
and silydianin (10 %) (Pradhan and Girish, 
2006). The silymarin content in milk thistle 
extracts may range from 40-80 %. Recom-
mended daily doses of milk thistle extract 
range between 210 to 800 mg, depending 
on patient characteristics and therapeutic 
objectives (Pradhan and Girish, 2006). The 
terms milk thistle, silymarin, and silybin are 
generally used interchangeably. 
In the United States and Europe, about 
65 % of patients with liver disease take 
herbal preparations. The cost of the use of 
silymarin reaches $ 180 million in Germany 
alone. In spite of the wealth of literature, 
there is no firm clinical evidence to endorse 
the use of these substances in clinical prac-
tice (Loguercio and Festi, 2011). This dis-
crepancy is attributed to various factors, 
such as quality of clinical trials, heterogene-
ity of diagnoses, lack of standardized prepa-
rations, and frequently inconsistent dosing 
and outcome parameters.  
A number of in vitro studies revealed 
that silymarin and silybin can exhibit inhi-
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bition of various CYP enzymes such as 
CYP3A4, CYP2C8, CYP2C9, CYP2C19, 
CYP2D6 and CYP2E1 (Budzinski et al., 
2007; Etheridge et al., 2007; Sridar et al., 
2004; Venkataramanan et al., 2000). The 
existing data suggest that the clearance of a 
variety of drugs may be reduced by con-
comitant use of milk thistle via inhibition of 
CYP enzymes. In contrast, there is no con-
clusive in vitro evidence that milk thistle 
would have considerable effects on the ac-
tivity of the drug transporter protein P-gp 
(Budzinski et al., 2007; Etheridge et al., 
2007). 
A number of clinical studies have been 
performed to assess the in vivo effects of 
milk thistle products on various CYP en-
zymes. Most of these were done by using 
specific probe drugs, so this allows us to 
identify and characterize the effects of milk 
thistle on specific metabolic pathways. In 
the very early work, silymarin at the lower 
end of usually recommended daily doses 
(Legalon®, 70 mg three times a day = 
210 mg/day) was given orally to 16 healthy 
subjects for 28 days. Their results have 
shown that co-administration of silymarin 
had no effect on the pharmacokinetics of 
the two non-specific CYP probes, aminopy-
rine or phenylbutazone (Leber and Knauff, 
1976). 
Later on, a defined pharmacokinetic 
drug interaction was conducted (Gurley et 
al., 2004) to determine whether long-term 
supplementation of milk thistle (Silybum 
marianum) extract affected CYP1A2, 
CYP2D6, CYP2E1, or CYP3A4 enzyme 
activity. The study was performed in 12 
healthy subjects who were randomly as-
signed to receive milk thistle (175 mg twice 
a day = 350 mg/day, standardized to 80 % 
silymarins) for 28 days. Probe drug cock-
tails of midazolam (CYP3A4) and caffeine 
(CYP1A2), followed 24 hours later by 
chlorzoxazone (CYP2E1) and debrisoquine 
(CYP2D6), were administered before (base-
line) and at the end of supplementation. 
Pre-supplementation and post-supplemen-
tation phenotypic trait assessments were 
determined for activity of CYP3A4, 
CYP1A2, CYP2E1, and CYP2D6. The re-
sults from this study showed that daily dos-
es of 350 mg of a standardized milk thistle 
extract did not affect human CYP1A2, 
CYP2D6, CYP2E1, and CYP3A4 enzyme 
activities in vivo. Therefore, the long term 
use of usual recommended dose of milk 
thistle does not appear to cause a significant 
interaction potential for drugs which are 
metabolized by these enzymes (Gurley et 
al., 2004).  
The same group of researchers conduct-
ed another similar pharmacokinetic study in 
19 healthy young subjects (Gurley et al., 
2006). The difference was the subjects were 
dosed with substantially higher daily doses 
of a standardized milk thistle supplement 
(900 mg/day) for 14 days. The subjects also 
received rifampin (300 mg twice a day) and 
clarithromycin (500 mg twice a day) for 7 
days as positive controls for CYP3A4 in-
duction and inhibition, respectively. Identi-
cal oral dose of midazolam (a CYP3A4 
probe substrate) was administered before 
and after milk thistle supplementation and 
control periods (Gurley et al., 2006). Unlike 
those observed for rifampin and clarithro-
mycin, midazolam pharmacokinetics were 
unaffected by milk thistle. Milk thistle sup-
plementation appears to have no clinically 
relevant effect on CYP3A activity in vivo. 
Thus, these results confirm the previous 
finding that milk thistle extract is not a clin-
ically relevant modulator of human 
CYP3A4 enzyme activity in vivo. However, 
given the inter-product variability in phyto-
chemical content, potency, and formulation 
among herbal supplements, these results 
may not extend to regimens utilizing higher 
dosages, longer supplementation periods, or 
brands with improved dissolution and/or 
bioavailability characteristics (Gurley et al., 
2006). 
Furthermore, a similar observation re-
garding the effect of milk thistle extract was 
found with another CYP3A4 probe drug, 
nifedipine (Fuhr et al., 2007). This pharma-
cokinetic study was conducted to determine 
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whether inhibition of CYP3A4 by silymarin 
is present in vivo. Immediate release nifedi-
pine (10 mg) was administered as a 
CYP3A4 probe drug either alone or with 
co-administration of silymarin (560 mg) to 
16 healthy volunteers. It was found that ni-
fedipine AUC was 13 % higher in the si-
lymarin period, and Cmax values were 
30 % lower than those of the baseline peri-
od. There was a trend to delayed absorption 
of nifedipine in the silymarin period. Intra-
individual variability especially for Cmax 
(intra-subject CV 120 %) was surprisingly 
high. Overall, this study confirmed that si-
lymarin is not a potent CYP3A4 inhibitor in 
vivo (Fuhr et al., 2007). Their data also 
suggest that co-administration of silymarin 
does not considerably alter the extent of 
absorption or metabolism of nifedipine but 
may delay the absorption rate (Fuhr et al., 
2007). This potential effect of silymarin co-
medication very much resembles the effect 
of food on pharmacokinetics of immediate-
ly release nifedipine, which probably is 
caused by delayed and more irregular gas-
tric emptying in the presence of food (Fuhr 
et al., 2007). 
There were two other pharmacokinetic 
studies on milk thistle and drug interac-
tions. These studies determined whether 
milk thistle extract may have the potential 
to alter the pharmacokinetics of the HIV 
protease inhibitor indinavir. Indinavir is a 
known CYP3A4 and P-gp substrate. In the 
first study (Piscitelli et al., 2002b), pharma-
cokinetics of indinavir was investigated in 
10 healthy volunteers. Blood samples were 
collected over 8 hours after the volunteers 
took four doses of indinavir 800 mg every 8 
hours for baseline pharmacokinetics. This 
dosing and sampling were repeated after the 
subjects took milk thistle 175 mg (con-
tained silymarin 153 mg as the active in-
gredient) three times a day for 3 weeks. Af-
ter an 11-day washout, indinavir dosing and 
blood sampling were repeated to evaluate 
the offset of any potential interaction. The 
results have demonstrated that milk thistle 
did not alter significantly the overall expo-
sure of indinavir, as evidenced by only 9 % 
reduction in the indinavir AUC after 3 
weeks of dosing with milk thistle (Piscitelli 
et al., 2002b). This suggests that milk this-
tle in commonly recommended dosages 
should not interfere with indinavir therapy 
in patients infected with the human immu-
nodeficiency virus. 
In the second study (DiCenzo et al., 
2003), pharmacokinetic drug interactions 
were evaluated in 10 healthy volunteers. 
Indinavir (800 mg, three times a day) was 
given for four doses on days 1 and 2. Si-
lymarin (160 mg, three times a day = 480 
mg/day) was given on days 3-15. On day 16 
and for one dose on day 17, both indinavir 
and silymarin were given at the same dos-
ages. Pharmacokinetic parameters of indi-
navir were assessed at steady state both be-
fore and after co-administration of si-
lymarin for 14 days. The results showed 
that pretreatment with silymarin for 14 days 
had no considerable effect on the AUC at 
steady state and the trough plasma concen-
tration of indinavir. So these indicate that 
silymarin has no apparent effect on the 
pharmacokinetics of indinavir. Taken to-
gether, both indinavir pharmacokinetic drug 
interaction studies generated consistent re-
sults, thus denoting that milk thistle extract 
supplementation at usually recommended 
dose does not modify the activity of 
CYP3A4 in vivo to a clinically relevant ex-
tent (DiCenzo et al., 2003). 
Another pharmacokinetic drug interac-
tion study was carried out to evaluate the 
effect of milk thistle root extract on the ac-
tivity of CYP3A4 (Rao et al., 2007). This 
study used the H2-receptor antagonist 
ranitidine as a model CYP3A4 substrate 
and ranitidine is also a putative P-gp sub-
strate. They found that there was no notable 
influence of silymarin on the pharmacoki-
netics of ranitidine. This was revealed by 
evidence showing that concomitant admin-
istration of silymarin (140 mg, three times a 
day for 7 days) did not alter ranitidine 
Cmax and AUC(0-infinity). So this finding 
of lack of effect of milk thistle on CYP3A4 
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activity, is consistent with those reported 
previously (Gurley et al., 2004, 2006). 
Van Erp and co-workers (van Erp et al., 
2005) conducted a study to examine wheth-
er milk thistle affects the pharmacokinetics 
of the anticancer drug irinotecan, a sub-
strate for CYP3A4 and UDP glucuronosyl-
transferase isoform 1A1 (UGT1A1) en-
zymes, in humans. The study involved 6 
cancer patients who were treated with iri-
notecan (125 mg/m2) given as a 90-minute 
infusion once weekly. Four days before the 
second irinotecan dose, patients received 
200 mg milk thistle capsules, three times a 
day (= 600 mg/day), for 14 consecutive 
days. Each milk thistle capsule contained 
200 mg milk thistle seed extract consisting 
of 80 % silymarin. Short-term (4 days) or 
more prolonged intake of milk thistle (12 
days) had no significant effect on clearance 
of irinotecan. Whereas the extent of glucu-
ronidation of the irinotecan’s metabolite 
SN-38 was relatively similar between pre-
supplementation and post-supplementation 
with milk thistle. These results suggested 
that the concentrations silybin achieved af-
ter intake of milk thistle at this usual re-
commended are too low to produce any 
significant effect on the activities of 
CYP3A4 and UGT1A1 in vivo (van Erp et 
al., 2005). Thus, herbal drug interaction 
with milk thistle is unlikely in regard to an-
ticancer drugs metabolized by these two 
enzymes. Moreover, Flaig et al. (2007) pro-
vided the best evidence that silybin can be 
administered to humans at doses producing 
anticancer-relevant concentrations, with 
minimal or no side effects. 
With respect to CYP2C9, an early clini-
cal study (Rajnarayana et al., 2004) was 
undertaken in 12 healthy volunteers to de-
termine the effects of milk thistle extract 
silymarin on the pharmacokinetics of met-
ronidazole (a substrate for CYP3A4 and 
CYP2C9). At first, subjects received met-
ronidazole alone at a dose of 400 mg every 
8 h for 3 days. On day 4, blood and urine 
were collected at different time points and 
metronidazole concentrations were meas-
ured. After a washout period of one week 
silymarin was given at a daily dose of 
140 mg for 9 days. From day 7 both si-
lymarin (140 mg/day) and metronidazole (3 
x 400 mg/day) were given till the 9th day. 
On day 10, blood and urine were collected 
as above and the concentrations of metroni-
dazole and its metabolite were determined. 
The results have shown that co-admini-
stration of silymarin increased the clearance 
of metronidazole and its major metabolite, 
hydroxymetronidazole both by approxi-
mately 30 %, with a concomitant decrease 
in half-life, Cmax and AUC. These findings 
indicate that silymarin might induce both 
intestinal P-glycoprotein and CYP3A4 up-
on multiple dose administration (Rajnara-
yana et al., 2004). However, this finding is 
in contrast with all other previous reports, 
and reserved further investigations to clari-
fy the issue and give insight to its underly-
ing mechanism(s). In addition, a recent 
study has reported that milk thistle extract 
pro-ducts significantly inhibited PXR-
mediated CYP3A4 induction by rifampicin, 
erlotinib and paclitaxel at the transcriptional 
level (Mooiman et al., 2013). Their results 
demonstrate that milk thistle is able to pre-
vent CYP3A4 induction and that silybin 
and isosilybin are responsible for this ef-
fect.  
Han et al. (2009) examined the effects 
of silymarin on the pharmacokinetics of the 
angiotensin II receptor antagonist losartan 
and its active metabolite E-3174 and its re-
lationship with CYP2C9 genotypes in 12 
healthy Chinese subjects. These subjects 
were of known CYP2C9 genotype (six 
CYP2C9*1/*1 and six CYP2C9*1/*3). The 
pharmacokinetics of losartan and E-3174 
were studied before and after a 14-day 
treatment with 140 mg of silymarin three 
times daily. The AUC of losartan increased 
(by approximately 2-fold) significantly fol-
lowing a 14-day silymarin treatment in sub-
jects with the CYP2C9*1/*1 genotype, but 
not in those with the CYP2C9*1/*3 geno-
type. Hence, the oral apparent clearance 
(CL/F) of losartan was also significantly 
EXCLI Journal 2014;13:347-391 – ISSN 1611-2156 
Received: July 12, 2013, accepted: March 20, 2014, published: April 02, 2014 
 
 
379 
decreased by more than 2-fold after a 14-
day silymarin treatment in these 
CYP2C9*1/*1 genotype subjects. On the 
other hand, in carriers of CYP2C9*1/*3, 
there were no significant differences in any 
pharmacokinetic parameters of losartan be-
tween the placebo and silymarin treatment 
groups. The AUC of E-3174 decreased sig-
nificantly with a silymarin pretreatment in 
both CYP2C9*1/*1 and the CYP2C9*1/*3 
subjects. The authors concluded that si-
lymarin inhibits the metabolism of losartan 
to E-3174, however the magnitude of the 
inhibition on CYP2C9 is different depend-
ent upon CYP2C9 genotypes (Han et al., 
2009). The findings from Han et al. (2009) 
were followed up by Brantley and co-
workers (Brantley et al., 2010) who did 
study in vitro and found that silybin A and 
silybin B were the most potent CYP2C9 
inhibiting constituents of silymarin extract. 
In systematic expressions, the available ev-
idence on CYP2C9-related issue suggests 
that milk thistle co-administration might 
have a potential to inhibit the clearance and 
to increase the exposure of other sensitive 
CYP2C9 substrates such as warfarin in vi-
vo. The consequence of this particular herb-
al supplement is remaining to be confirmed 
by clinical investigations. 
Gurley and co-workers (Gurley et al., 
2008b) evaluated the effect of milk thistle 
extract on the activity of human CYP2D6 in 
16 healthy volunteers. Subjects were ran-
domized to receive a standardized milk 
thistle extract for 14 days on separate occa-
sions. Debrisoquine (a CYP2D6 probe) was 
administered before (baseline) and at the 
end of milk thistle supplementation. Pre- 
and post-supplementation phenotypic trait 
measurements were determined for CYP-
2D6 activity. Comparisons of pre- and post-
supplementation results revealed no signifi-
cant effect of milk thistle supplementation 
on human CYP2D6 activity. Accordingly, 
adverse herbal drug interactions are unlike-
ly to occur when the patients taking milk 
thistle concomitantly with prescription 
drugs which are metabolized by CYP2D6 
enzyme. 
Overall, the existing evidence from clin-
ical interaction studies is reasonably con-
sistent and suggests that milk thistle or si-
lymarin products consumed at recommend-
ed doses; do not change the activities of 
CYP3A4, CYP1A2, CYP2D6, and 
CYP2E1 enzymes. The evidence supporting 
a lack of interaction potential is most strong 
for CYP3A4. Also the findings from a sin-
gle study in irinotecan-treated cancer pa-
tients suggest that co-administration of milk 
thistle or silymarin products is unlikely to 
markedly modify the activity of UGT1A1 
and carboxylesterase 2 enzymes. On the 
other hand, the available evidence regard-
ing CYP2C9 from a well-designed study in 
Chinese subjects (Han et al., 2009) con-
vincingly proposes the possibility of signif-
icant inhibition of CYP2C9 by milk thistle 
or silymarin products. These findings invite 
for further studies to confirm the clinical 
implication of this interaction, especially 
with narrow therapeutic index CYP2C9 
drugs such as warfarin. 
 
Special consideration for elderly patients 
Herbal medicines and dietary supple-
ment use is common in the elderly (Olesen 
et al., 2013). The concomitant use of pre-
scription medications and herbal products 
by the elderly is also a common situation 
(Izzo, 2012). Many older patients do not 
disclose their use of the herbal dietary sup-
plements to their physicians. In addition, 
because older adults have multiple health 
problems, they are particular at risk for 
herbal drug interactions. Special concerns 
have been raised for elderly patients be-
cause of well-documented polypharmacy 
interactions, increased sensitivity to certain 
drugs, and diminished metabolism of many 
drugs. These can potentially increase the 
risk of adverse events from herbal drug in-
teractions. In spite of this, clinical studies 
targeted at exploring the herbal drug inter-
actions in elderly patients are limited. 
Gurley et al. (2005a) found that elderly sub-
EXCLI Journal 2014;13:347-391 – ISSN 1611-2156 
Received: July 12, 2013, accepted: March 20, 2014, published: April 02, 2014 
 
 
380 
jects, like their younger counterparts, are 
susceptible to herb-mediated changes in 
CYP activity and that some age-related 
changes in CYP responsivity to herbal 
products may exist. Gurley et al. (2005a) 
reported that ginseng marginally inhibited 
CYP2D6 in elderly subjects. On the other 
hand, no such inhibition was observed in 
young subjects (Gurley et al., 2002). It is 
recommended that concomitant ingestion of 
herbal supplements with prescription medi-
cations should be strongly discouraged in 
the elderly. 
 
CONCLUSIONS 
Abundant research data have shown that 
herbal supplements or herbal medicines can 
modify drug metabolism mediated by hu-
man CYP enzymes. This causes herbal drug 
interaction which has the clinical conse-
quence of adversely affecting the pharma-
cokinetics of several drugs. Thus, when die-
tary supplements are taken concomitantly 
with prescription drugs, this can result in 
serious herbal drug interactions. This may 
be likely to happen when multiple drugs, 
and multiple herbal supplements are taken 
concurrently. However, as noted in this ar-
ticle, the drug interactions do not appear to 
happen with every single herbal supplement 
and with every drug. This is somewhat sim-
ilar to grapefruit drug interactions in which 
grapefruit or grapefruit juice does not inter-
act with every drug. As we have discovered 
the mechanism of the grapefruit drug inter-
actions, it was revealed that there are cer-
tain characteristics of the drug required for 
the interactions to happen. These are that 
the drug has to be mainly metabolized by 
CYP3A4 and possess low oral bioavailabi-
lity (Bailey et al., 2013; Ho et al., 2000; 
Shimomura et al., 2003). Regarding herbal 
drug interactions, the clinical implications 
of the interaction is dependent on a variety 
of factors, such as characteristics of co-
administered drugs, the involved CYP en-
zymes, active constituents of the herb, the 
applied dosage regimens, and health status 
of the patients. The drug interactions with 
St. John’s wort represent the best studied 
drug interactions among the other botanical 
supplements. The numerous data available 
revealed that the active ingredient hyperfor-
in has a strong affinity for the pregnane xe-
nobiotic receptor (PXR) and thus acts as a 
potent inducer of CYP3A4. Consequently, 
CYP3A4 induction caused by St. John’s 
wort can reduce the oral bioavailability of 
many drugs making the drug less effective. 
If a drug with a narrow therapeutic index 
(e.g. warfarin or cyclosporine A) is in-
volved, the interactions may cause serious 
or occasionally life-threatening adverse ef-
fects. The experience with the St. John’s 
wort case shows that there was so much 
useful information that we know about this 
interesting interaction. These include the 
mechanism of the interaction, the active 
herbal interaction involved, the particular 
CYP enzymes induced or inhibited by St. 
John’s wort, etc. This information is very 
useful and can help us predict herbal drug 
interactions, thus the adverse drug interac-
tions can be avoided and helps make the 
use of herbal supplements safe for patients. 
With respect to other herbal supplements, 
this comprehensive data have not been 
completed. For example identification of 
the major active constituents in herbal 
products that are responsible for drug inter-
actions with specific herbal supplement is 
required to be undertaken. Also characteri-
zation of the interaction by individual ac-
tive constituent and mechanism of the in-
teraction need to be studied in detail. 
With regard to future research, it is 
worth to note that there are numerous re-
search on herbal drug interactions that have 
been conducted in vitro and in animals. In 
vitro studies are useful for providing mech-
anistic information and assessing various 
components in herbal medicines. In general, 
characterization of these processes assists 
prediction of interactions between herbal 
supplements and conventional drugs that 
may put the patient’s health at risk. Alt-
hough these experiments are relatively easy 
to carry out but they suffer from limitations 
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in extrapolating the results obtained from 
these studies to clinical situations (Goey et 
al., 2013; Hermann and von Richter, 2012). 
It is not uncommon to find that the findings 
observed from in vitro studies were incon-
sistent with those found in clinical studies. 
Clinical studies are needed for conﬁrmation 
and evaluation of the clinical relevance of 
herbal drug interaction results obtained 
from in vitro studies. Despite the progress 
having been attained over the previous 
years, the overall number of clinical studies 
on herbal drug interactions still seems inad-
equate. A need for additional well-designed 
clinical studies is desirable as these will as-
sist in confirming the in vitro studies and 
help assess the clinical significance of these 
potential interactions. We agree with Her-
mann and von Richter (2012) that there are 
numerous interactions studies with warfa-
rin, a narrow therapeutic index drug and a 
CYP2C9 substrate. Whereas studies with 
other narrow therapeutic index drugs are 
scarce. The exceptions to this were for cy-
closporine A and antiretroviral drugs. Thus, 
clinical studies to verify whether herbal 
drug interactions exist with respect to other 
narrow therapeutic index drugs are warrant-
ed.  
There is also limited information on the 
pharmacokinetics and pharmacodynamics 
of herbal supplements or herbal medicines 
per se. Without this comprehensive data, it 
is difficult to characterize and predict the 
interactions that may occur. It is also neces-
sary to understand the mechanisms of herb-
al drug interactions to assist this process. 
The study of herbal drug interactions is fur-
ther complicated by the nature of the herbal 
supplements. The manufacture of herbal 
supplements or medicines is not subject to 
the same regulations as prescription drugs. 
Thus the content of the active ingredients 
may vary among manufacturers, potentially 
causing a large variation in efficacy and 
safety. The ingredients specified on the la-
bels of herbal products may be incomplete 
or incorrect. The herbal ingredients could 
also vary from batch to batch due lack of 
quality control. Even though sources and 
specification of herbs have been cited in 
many studies of herbal drug interactions, 
generally it is very difficult to generalize 
and compare the results derived from dif-
ferent studies because of this. Often we see 
contradictory findings obtained from sepa-
rate investigations. Occasionally, it was 
suspected that the differences in their re-
sults were related to different methology 
approaches used. However, as the herbal 
supplements are not precisely regulated, the 
difference in the active ingredients of the 
particular herbal supplement used cannot be 
ruled out. Products from different manufac-
turers of the same herb may have different 
chemical compositions and hence different 
biological actions. It has been suggested 
that the same rigorous regulations that ap-
ply to conventional drugs with regard to 
quality, safety and efficacy should be re-
quired for herbal supplements. There is a 
distinct necessity for well designed clinical 
trials, pre-marketing approvals regarding 
labelling and safety, and comprehensive 
post-marketing surveillance systems for 
monitoring the adverse effects of herbal 
drug interactions. 
An important herbal drug interaction is 
St. John’s wort drug interactions. St. John’s 
wort is remarkably problematic in relation 
to its ability to induce CYP3A4, an enzyme 
that metabolizes more than 50 % of all pre-
scription medications. The extraordinary 
effect of St. John’s wort clearly shows the 
caution is needed when this herb is used by 
patients who are taking other drugs that are 
metabolized by CYP3A4. Garlic and milk 
thistle extracts do not cause severe drug in-
teractions in humans. There have been in-
consistent results reported on the effects of 
sylibin, which is one of the active compo-
nents of milk thistle. Currently, we recog-
nize that many herbal drug interactions are 
possible; some of these are a serious risk to 
the health of our patients. Interactions be-
tween herbal supplements and drugs often 
lead to toxicity and loss of therapeutic effi-
cacy. Therefore it is essential that health-
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care professionals are well informed about 
this fast growing field. Consequently 
healthcare professionals should check if 
their patients are using herbal supplements. 
Patients should be encouraged to inform 
their healthcare providers which herbal 
supplements or herbal medicines they are 
taking so that the risk of herbal drug inter-
actions can be prevented or minimized with 
appropriate management and to ensure that 
consuming herbal medicines is safe as pos-
sible. 
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